SEC Form DEF 14A filed by Bicara Therapeutics Inc.
$BCAX
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
| ☐ | Preliminary Proxy Statement | ||||
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | ||||
| ☒ | Definitive Proxy Statement | ||||
| ☐ | Definitive Additional Materials | ||||
| ☐ | Soliciting Material Pursuant to §240.14a-12 | ||||
(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply)
| ☒ | No fee required. | ||||
| ☐ | Fee paid previously with preliminary materials. | ||||
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Securities Exchange Act of 1934 Rules 14a-6(i)(1) and 0-11. | ||||
BICARA THERAPEUTICS INC.
116 Huntington Avenue, Suite 703
Boston, MA 02116
NOTICE OF 2025 ANNUAL MEETING OF STOCKHOLDERS
To be held June 9, 2025
Notice is hereby given that the 2025 Annual Meeting of Stockholders of Bicara Therapeutics Inc. (the “Annual Meeting”) will be held online on June 9, 2025 at 9:00 a.m. Eastern Time. The Annual Meeting will be held virtually, and you may attend the meeting via the Internet at www.virtualshareholdermeeting.com/BCAX2025, where you will be able to vote electronically and submit questions. You will need the 16-digit control number included with the Notice of Internet Availability of Proxy Materials being mailed to you separately in order to attend the Annual Meeting.
Stockholders of record at the close of business on April 14, 2025, the record date for the Annual Meeting, are entitled to notice of, and to vote at, the Annual Meeting or any adjournment or postponement of the Annual Meeting. The purpose of the Annual Meeting is the following:
1.To elect three class I directors to our board of directors, to serve until the 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal;
2.To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; and
3.To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
You can find more information on each of the matters to be voted on at the Annual Meeting, including information regarding the nominees for election to our board of directors, in the accompanying proxy statement. The board of directors recommends a vote “FOR” the election of each of the three nominees for class I directors and “FOR” the ratification of the appointment of our independent registered public accounting firm for the fiscal year ending December 31, 2025.
This year, the Company is following the Securities and Exchange Commission’s “Notice and Access” rule that allows companies to furnish their proxy materials by posting them on the Internet. As a result, we are mailing to our stockholders a Notice of Internet Availability of Proxy Materials (the “Notice”) instead of a paper copy of the accompanying proxy statement and our Annual Report for the fiscal year ended December 31, 2024 (the “2024 Annual Report”). We are mailing the Notice on or about April 25, 2025, and it contains instructions on how to access both the 2024 Annual Report and accompanying proxy statement (the “Proxy Materials”) over the Internet. This method provides our stockholders with expedited access to Proxy Materials and not only lowers the cost of printing and distribution but also reduces the environmental impact of the Annual Meeting. If you would like to receive a print version of the Proxy Materials, free of charge, please follow the instructions on the Notice.
To attend the Annual Meeting virtually via the Internet, please visit www.virtualshareholdermeeting.com/BCAX2025. You will not be able to attend the Annual Meeting in person.
Whether or not you expect to attend the Annual Meeting online, we encourage you to read the accompanying proxy statement and vote your shares as promptly as possible to ensure your representation and the presence of a quorum at the Annual Meeting on the Internet as described in the instructions included in the Notice by voting online at www.proxyvote.com. If you requested and received a paper copy of the Proxy Materials, you can vote by signing, dating and returning the enclosed proxy card, calling 1-800-690-6903 and following the recorded instructions, or online at www.proxyvote.com. If you vote your shares on the Internet or by telephone, you will need to enter the 16-digit control number provided in the Notice.
Your vote is important regardless of the number of shares you own. If you attend the Annual Meeting online, you may vote your shares during the Annual Meeting virtually via the Internet even if you previously voted your proxy. Your proxy is revocable in accordance with the procedures set forth in the proxy statement.
If your shares are held in “street name,” that is, held for your account by a broker or other nominee, you will receive instructions from the holder of record that you must follow for your shares to be voted.
| By order of the board of directors, | ||||||||
| /s/ Claire Mazumdar | ||||||||
| Claire Mazumdar, Ph.D., M.B.A. | ||||||||
| Chief Executive Officer | ||||||||
Boston, Massachusetts
April 25, 2025
Table of Contents
| Page | ||||||||||||||
PROXY STATEMENT | 6 | |||||||||||||
PROPOSAL NO. 1 – ELECTION OF CLASS I DIRECTORS | 13 | |||||||||||||
PROPOSAL NO. 2 – RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS BICARA’S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025 | 18 | |||||||||||||
CORPORATE GOVERNANCE | 20 | |||||||||||||
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS | 42 | |||||||||||||
PRINCIPAL STOCKHOLDERS | 47 | |||||||||||||
REPORT OF THE AUDIT COMMITTEE | 51 | |||||||||||||
HOUSEHOLDING | 52 | |||||||||||||
STOCKHOLDER PROPOSALS | 52 | |||||||||||||
OTHER MATTERS | 53 | |||||||||||||
BICARA THERAPEUTICS INC.
116 Huntington Avenue, Suite 703
Boston, MA 02116
PROXY STATEMENT
FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD June 9, 2025
This proxy statement contains information about the 2025 Annual Meeting of Stockholders, or the Annual Meeting, of Bicara Therapeutics Inc., which will be held on June 9, 2025 at 9:00 a.m. Eastern Time. The board of directors of Bicara Therapeutics Inc. is using this proxy statement to solicit proxies for use at the Annual Meeting. In this proxy statement, the terms “Bicara Therapeutics,” “we,” “us,” and “our” refer to Bicara Therapeutics Inc. The mailing address of our principal executive office is Bicara Therapeutics Inc., 116 Huntington Avenue, Suite 703, Boston, MA 02116.
All properly submitted proxies will be voted in accordance with the instructions contained in those proxies. If no instructions are specified, the proxies will be voted in accordance with the recommendation of our board of directors with respect to each of the matters set forth in the accompanying Notice of Meeting. You may revoke your proxy at any time before it is exercised at the meeting by giving our corporate secretary written notice to that effect.
We will make our proxy statement and our Annual Report to Stockholders for the fiscal year ended December 31, 2024 available to stockholders on or about April 25, 2025.
We are an “emerging growth company” under applicable federal securities laws and therefore permitted to conform with certain reduced public company reporting requirements. As an emerging growth company, we provide in this proxy statement the scaled disclosure permitted under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, including the compensation disclosures required of a “smaller reporting company,” as that term is defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934, as amended, or the Exchange Act. In addition, as an emerging growth company, we are not required to conduct votes seeking approval, on an advisory basis, of the compensation of our named executive officers or the frequency with which such votes must be conducted, and we are not required to provide pay versus performance disclosure under Item 402(v) of Regulation S-K. We will remain an “emerging growth company” until the earliest of (i) the last day of the fiscal year following the fifth anniversary of our initial public offering in September 2024; (ii) the last day of the fiscal year in which our total annual gross revenue is equal to or more than $1.235 billion; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission or the SEC. Even after we are no longer an “emerging growth company,” we may remain a “smaller reporting company.”
Important Notice Regarding the Availability of Proxy Materials for
the Annual Meeting of Stockholders to be Held on June 9, 2025:
This proxy statement and our 2024 Annual Report to Stockholders are
available for viewing, printing and downloading at https://materials.proxyvote.com/BCAX2025
6
A copy of our 2024 Annual Report, as filed with the SEC, except for exhibits, will be furnished without charge to any stockholder upon written request to Bicara Therapeutics Inc., 116 Huntington Avenue, Suite 703, Boston, MA 02116, Attention: Corporate Secretary. This proxy statement and our 2024 Annual Report are also available on the SEC’s website at www.sec.gov.
7
BICARA THERAPEUTICS INC
PROXY STATEMENT
FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS
GENERAL INFORMATION
When are this proxy statement and the accompanying materials scheduled to be sent to stockholders?
We have elected to provide access to our Proxy Materials to our stockholders via the Internet. Accordingly, on or about April 25, 2025, we will begin mailing a Notice of Internet Availability of Proxy Materials, or Notice. Our Proxy Materials, including the Notice of the 2025 Annual Meeting of Stockholders, this proxy statement and the accompanying proxy card or, for shares held in street name (i.e., held for your account by a broker or other nominee), a voting instruction form, and the 2024 Annual Report to Stockholders, or 2024 Annual Report, will be mailed or made available to stockholders on the Internet on or about the same date.
Why did I receive a Notice of Internet Availability of Proxy Materials instead of a full set of proxy materials?
Pursuant to rules adopted by the SEC, for most stockholders, we are providing access to our Proxy Materials over the Internet rather than printing and mailing our Proxy Materials. We believe following this process will expedite the receipt of such materials and will help lower our costs and reduce the environmental impact of our annual meeting materials. Therefore, the Notice will be mailed to holders of record and beneficial owners of our common stock starting on or about April 25, 2025. The Notice provides instructions as to how stockholders may access and review our Proxy Materials, including the Notice of the 2025 Annual Meeting of Stockholders, this Proxy Statement, the proxy card and our 2024 Annual Report, on the website referred to in the Notice or, alternatively, how to request that a copy of the Proxy Materials, including a proxy card, be sent to them by mail. The Notice also provides voting instructions. In addition, stockholders of record may request to receive the proxy materials in printed form by mail or electronically by e-mail on an ongoing basis for future stockholder meetings. Please note that, while our Proxy Materials are available at the website referenced in the Notice, and our Notice of the 2025 Annual Meeting of Stockholders, this Proxy Statement and our 2024 Annual Report are available on our website, no other information contained on either website is incorporated by reference in or considered to be a part of this Proxy Statement.
Who is soliciting my vote?
Our board of directors is soliciting your vote for the Annual Meeting, including at any adjournments or postponements of the meeting.
When is the record date for the Annual Meeting?
The record date for determination of stockholders entitled to vote at the Annual Meeting is the close of business on April 14, 2025.
How many votes can be cast by all stockholders?
There were 54,536,218 shares of our common stock, par value $0.0001 per share, outstanding on April 14, 2025, all of which are entitled to vote with respect to all matters to be acted upon at the Annual Meeting on June 9, 2025. Each stockholder of record is entitled to one vote for each share of our common stock held by such stockholder. None of our shares of undesignated preferred stock were outstanding as of April 14, 2025.
Who is entitled to vote?
Registered Stockholders. If shares of our common stock are registered directly in your name with our transfer agent, you are considered the stockholder of record with respect to those shares. As the stockholder of record, you have the right to grant your voting proxy directly to the individuals listed on the proxy card or vote on your own
8
behalf at our virtual Annual Meeting. Throughout this proxy statement, we refer to these registered stockholders as “stockholders of record.”
Street Name Stockholders. If shares of our common stock are held on your behalf in a brokerage account or by a bank or other nominee, you are considered to be the beneficial owner of shares that are held in “street name,” and the Proxy Materials were forwarded to you by your broker or nominee, who is considered the stockholder of record with respect to those shares. As the beneficial owner, you have the right to direct your broker, bank or other nominee as to how to vote your shares. Beneficial owners are also invited to attend our virtual Annual Meeting. However, since a beneficial owner is not the stockholder of record, you may not vote your shares of our common stock on your own behalf at the Annual Meeting unless you follow your broker’s procedures for obtaining a legal proxy. Note you should also be receiving a voting instruction form for you to use from your broker. Throughout this proxy statement, we refer to stockholders who hold their shares through a broker, bank or other nominee as “street name stockholders.”
How do I vote?
If you are a stockholder of record, there are several ways for you to vote your shares.
•Online. You may vote at www.proxyvote.com, 24 hours a day, seven days a week. You will need the 16-digit control number included on your Notice. Votes submitted online must be received by 11:59 p.m. Eastern Time, on June 8, 2025.
•By Telephone. You may vote using a touch-tone telephone by calling 1-800-690-6903, 24 hours a day, seven days a week. You will need the 16-digit control number included on your Notice. Votes submitted by telephone must be received by 11:59 p.m. Eastern Time, on June 8, 2025.
•By Mail. If you requested and received a paper copy of the Proxy Materials you may vote by mail by completing, signing and dating the enclosed proxy card and returning it in the enclosed prepaid envelope. Votes submitted through the mail must be received by June 8, 2025.
•By QR Code. You may vote by scanning the QR code on your proxy card with your mobile device. Votes submitted by QR code must be received by 11:59 p.m. Eastern Time on June 8, 2025.
•During the Annual Meeting. You may vote during the Annual Meeting by going to www.virtualshareholdermeeting.com/BCAX2025. You will need the 16-digit control number included on your proxy card.
If the Annual Meeting is adjourned or postponed, the deadlines above may be extended.
The voting deadlines and availability of telephone and Internet voting for beneficial owners of shares held in “street name” will depend on the voting processes of the organization that holds your shares. Therefore, we urge you to carefully review and follow the voting instruction card and any other materials that you receive from that organization. If you hold your shares of Bicara Therapeutics Inc. common stock in multiple accounts, you should vote your shares as described in each set of proxy materials you receive.
How do I vote by proxy?
If you will not be attending the Annual Meeting, you may vote by proxy. You can vote by proxy over the Internet by following the instructions provided in the enclosed proxy card. Proxies submitted by mail must be received before the start of the Annual Meeting.
If you submit a proxy without giving voting instructions, your shares will be voted in the manner recommended by the board of directors on all matters presented in this proxy statement, and as the persons named as proxies in the proxy card may determine in their discretion with respect to any other matters properly presented at the Annual Meeting. You may also authorize another person or persons to act for you as proxy in a writing, signed by you or your authorized representative, specifying the details of those proxies’ authority. The original writing must be given to each of the named proxies, although it may be sent to them by electronic transmission if, from that transmission, it can be determined that the transmission was authorized by you.
9
If any other matters are properly presented for consideration at the Annual Meeting, including, among other things, consideration of a motion to adjourn the Annual Meeting to another time or place (including, without limitation, for the purpose of soliciting additional proxies), the persons named in your proxy and acting thereunder will have discretion to vote on those matters in accordance with their best judgment. We do not currently anticipate that any other matters will be raised at the Annual Meeting.
How can I virtually attend the Annual Meeting?
To attend and participate in the Annual Meeting, stockholders will need to access the live webcast of the meeting. To do so, stockholders of record will need to visit www.virtualshareholdermeeting.com/BCAX2025, and beneficial owners of shares held in street name will need to follow the instructions provided in the voting instructions form by the broker, bank or other nominee that holds their shares.
The live webcast of the Annual Meeting will begin promptly at 9:00 a.m. Eastern Time on June 9, 2025. We encourage stockholders to login to this website and access the webcast before the Annual Meeting’s start time by following the instructions in the email received prior to the morning of the Annual Meeting. You should allow ample time in advance of the meeting.
Additionally, questions regarding how to attend and participate via the Internet can be answered by following the assistance instructions included on the virtual meeting website (www.virtualshareholdermeeting.com/BCAX2025) or by calling the phone number provided on the virtual meeting website on the day of the Annual Meeting.
If you wish to submit a question during the Annual Meeting, you may log into, and submit a question on, the virtual meeting platform using the unique link provided to you on your proxy card and following the instructions there. Our Annual Meeting will be governed by the Annual Meeting’s Rules of Conduct, which will address the ability of stockholders to ask questions during the meeting and rules for how questions will be recognized and addressed. The Annual Meeting’s Rules of Conduct will be available during the meeting on the virtual meeting website (www.virtualshareholdermeeting.com/BCAX2025).
How do I revoke my proxy?
You may revoke your proxy by (1) following the instructions on the Notice and entering a new vote by mail that we receive before the start of the Annual Meeting or over the Internet by the cutoff time of 11:59 p.m. Eastern Time on June 8, 2025, (2) attending and voting at the Annual Meeting (although attendance at the Annual Meeting will not in and of itself revoke a proxy), or (3) by filing an instrument in writing revoking the proxy or another duly executed proxy bearing a later date with our corporate secretary. Any written notice of revocation or subsequent proxy card must be received by our corporate secretary prior to the taking of the vote at the Annual Meeting. Such written notice of revocation or subsequent proxy card should be hand delivered to our corporate secretary or sent to our principal executive offices at Bicara Therapeutics Inc., 116 Huntington Avenue, Suite 703, Boston, MA 02116, Attention: Corporate Secretary.
If a broker, bank, or other nominee holds your shares, you must contact such broker, bank, or nominee in order to find out how to change your vote.
How is a quorum reached?
Our Third Amended and Restated Bylaws, or bylaws, provide that the presence, in person, by remote communication, if applicable, or by proxy duly authorized, of the holders of a majority of the outstanding shares of stock entitled to vote, will constitute a quorum for the transaction of business at the Annual Meeting. Under the General Corporation Law of the State of Delaware, shares that are voted “abstain” or “withheld” and broker “non-votes” are counted as present for purposes of determining whether a quorum is present at the Annual Meeting. If a quorum is not present, the meeting may be adjourned until a quorum is obtained. There were 54,536,218 shares of common stock outstanding and entitled to vote on April 14, 2025, our record date. Therefore, a quorum will be
10
present if 27,268,110 shares of our common stock are present in person or represented by executed proxies timely received by us at the Annual Meeting. Shares present virtually during the Annual Meeting will be considered shares of common stock represented in person at the meeting.
How is the vote counted?
Under our bylaws, to be elected, each of the directors nominated in Proposal No. 1 must receive a plurality of the shares present in person, by remote communication, if applicable, or represented by proxy duly authorized at the meeting and entitled to vote generally on the election of directors, meaning that the director nominees receiving the highest number of affirmative votes will be elected as directors. You may vote for all the director nominees, withhold authority to vote your shares for all the director nominees or withhold authority to vote your shares with respect to any one or more of the director nominees. Withholding authority to vote your shares with respect to one or more director nominees will have no effect on the election of directors. Broker non-votes are not considered votes cast and will have no effect on the election of directors. A broker “non-vote” occurs when a nominee holding shares for a beneficial owner does not vote on a particular proposal because the nominee does not have discretionary voting power with respect to that item and has not received instructions from the beneficial owner.
Under our bylaws, any proposal other than an election of directors is decided by the affirmative vote of a majority of the votes properly cast for and against such proposal, except where a larger vote is required by law or by our Fifth Amended and Restated Certificate of Incorporation, or certificate of incorporation, or our bylaws. Abstentions and Broker “non-votes” will be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the Annual Meeting but will not be counted as votes cast and will have no effect on the outcome of the vote for such proposal.
If your shares are held in “street name” by a brokerage firm, your brokerage firm is required to vote your shares according to your instructions. If you do not give instructions to your brokerage firm, the brokerage firm will still be able to vote your shares with respect to certain “discretionary” items but will not be allowed to vote your shares with respect to “non-discretionary” items.
The election of directors (Proposal No. 1) is a “non-discretionary” item. If you do not instruct your broker how to vote your shares with respect to this proposal, your broker may not vote for this proposal, and those shares will be counted as broker “non-votes.” Proposal No. 2 is considered to be a discretionary item, and your brokerage firm will be able to vote your shares on this proposal even if it does not receive instructions from you. Accordingly, we do not anticipate that there will be any broker non-votes on this proposal; however, any broker non-votes will not be counted as “votes cast” and will therefore have no effect on this proposal.
Who pays the cost for soliciting proxies?
We are making this solicitation and will pay the entire cost of preparing and distributing the Notice and our Proxy Materials and soliciting votes. If you choose to access the Proxy Materials or vote over the Internet, you are responsible for any Internet access charges that you may incur. Our officers and employees may, without compensation other than their regular compensation, solicit proxies through further mailings, personal conversations, facsimile transmissions, e-mails, or otherwise. We have hired Broadridge Financial Solutions, Inc. to assist us in the distribution of proxy materials. Proxy solicitation expenses that we will pay include those for preparation, mailing, returning, and tabulating the proxies.
How may stockholders submit matters for consideration at next year’s annual meeting?
The required notice must be in writing and received by our corporate secretary at our principal executive offices not later than the close of business on March 11, 2026, nor earlier than the close of business on February 9, 2026 (not less than 90 days nor more than 120 days prior to the first anniversary of the Annual Meeting). However, in the event that the date of next year’s annual meeting is advanced by more than 30 days, or delayed by more than 60 days, from the first anniversary of the Annual Meeting, or if no annual meeting was held in the preceding year, a stockholder’s notice must be so received no earlier than the 120th day prior to such annual meeting and not later than the close of business on the later of (A) the 90th day prior to such annual meeting and (B) the tenth day
11
following the day on which notice of the date of such annual meeting was mailed or public disclosure of the date of such annual meeting was made, whichever first occurs. In addition, to comply with the SEC’s universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than our nominees must provide notice by the same deadline noted herein to submit matters for consideration at the annual meeting. Such notice must comply with the additional requirements of Rule 14a-19(b).
In addition, any stockholder proposal intended to be included in the proxy statement for the next annual meeting of our stockholders in 2026 must also satisfy the requirements of SEC Rule 14a-8 under the Exchange Act, and be received not later than December 26, 2025. If the date of the annual meeting is moved by more than 30 days from the date contemplated at the time of the previous year’s proxy statement, then notice must be received within a reasonable time before we begin to print and send proxy materials. If that happens, we will publicly announce the deadline for submitting a proposal in a press release or in a document filed with the SEC.
How can I get help if I have trouble checking in or listening to the meeting online?
If you encounter any difficulties accessing the virtual meeting during the check-in or meeting time, please refer to the instructions on the virtual meeting website and the phone number made available the day of the meeting on the virtual meeting website.
How can I know the voting results?
We plan to announce preliminary voting results at the Annual Meeting. Final voting results will be published in a Current Report, on Form 8-K ("Form 8-K"), that we expect to file with the SEC within four business days after the Annual Meeting. If final voting results are not available to us in time to file a Form 8-K within four business days after the Annual Meeting, we intend to file a Form 8-K to publish preliminary results and, within four business days after the final results are known to us, file an additional Form 8-K to publish the final results.
12
PROPOSAL NO. 1 – ELECTION OF CLASS I DIRECTORS
Our board of directors currently consists of ten members. In accordance with the terms of our certificate of incorporation and bylaws, our board of directors is divided into three classes, class I, class II and class III, with members of each class serving staggered three-year terms. The members of the classes are divided as follows:
•the class I directors are Kiran Mazumdar-Shaw, Jake Simson, Ph.D. and Ryan Cohlhepp, Pharm.D., and their terms will expire at the Annual Meeting;
•the class II directors are Nils Lonberg, Ph.D., Christopher Bowden M.D. and Carolyn Ng, Ph.D. and their terms will expire at the annual meeting of stockholders to be held in 2026; and
•the class III directors are Claire Mazumdar, Ph.D., M.B.A., Kate Haviland, M.B.A., Scott Robertson, M.B.A. and Michael Powell, Ph.D. and their terms will expire at the annual meeting of stockholders to be held in 2027.
Upon the expiration of the term of a class of directors, directors in that class will be eligible to be elected for a new three-year term at the annual meeting of stockholders in the year in which their term expires.
Our certificate of incorporation and bylaws provide that the authorized number of directors may be changed only by resolution of our board of directors. Our certificate of incorporation also provides that our directors may be removed only for cause by the affirmative vote of the holders of at least two-thirds (2/3) of the outstanding shares then entitled to vote in an annual election of directors, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office.
This year, the term of our class I directors, Kiran Mazumdar-Shaw, Jake Simson, Ph.D. and Ryan Cohlhepp, Pharm.D., is expiring. The nominees are presently directors and have indicated a willingness to continue to serve as directors, if elected. If any nominee becomes unable or unwilling to serve, however, the proxies may be voted for a substitute nominee selected by our board of directors.
Our Corporate Governance Guidelines provide that the value of diversity should be considered in determining director candidates as well as other factors such as a candidate’s character, judgment, skills, education, expertise and absence of conflicts of interest. Our priority in selection of board members is identification of members who will further the interests of our stockholders through their established records of professional accomplishment, their ability to contribute positively to the collaborative culture among board members, and their knowledge of our business and understanding of the competitive landscape in which we operate and adherence to high ethical standards. The nominating and corporate governance committee and the full board of directors are committed to creating a board of directors with diversity, including diversity of expertise, experience, background and gender, and are committed to identifying, recruiting and advancing candidates offering such diversity in future searches.
In addition to the information presented below regarding each of the nominees and continuing directors’ specific experience, qualifications, attributes and skills that our board of directors and our nominating and corporate governance committee considered in determining that he or she should serve as a director, we also believe that each of our directors has demonstrated business acumen, integrity and an ability to exercise sound judgment, as well as a commitment of service to Bicara Therapeutics and our board of directors.
Nominees for Election as Class I Directors
The following table identifies our director nominees, and sets forth their principal occupation and business experience during the last five years and their ages as of April 14, 2025.
13
| Name | Positions and Offices Held with Bicara | Director Since | Age | |||||||||||||||||
Kiran Mazumdar-Shaw | Director | 2018 | 72 | |||||||||||||||||
Jake Simson, Ph.D. | Director | 2023 | 39 | |||||||||||||||||
Ryan Cohlhepp, Pharm.D. | Director, President and Chief Operating Officer | 2024 | 48 | |||||||||||||||||
Kiran Mazumdar-Shaw, has served as a member of our board of directors since December 2018. Ms. Mazumdar-Shaw founded Biocon Limited, an innovation-led global biopharmaceuticals company, in 1978 and has served as the Executive Chairperson since November 1978. Additionally, Ms. Mazumdar-Shaw has served as the Executive Chairperson of Biocon Biologics Limited, a unique, fully integrated, global biosimilars company since January 2021. She is also serving as the Non-Executive Chairperson of Syngene International Limited, an innovation-led contract research, development and manufacturing organization since April 2020. Ms. Mazumdar-Shaw also serves on the boards of directors of various private companies, educational institutions and holds key positions in certain governmental bodies. Ms. Mazumdar-Shaw holds a B.Sc Honours degree in Zoology from Central College, Bangalore University and Post-Graduate in Malting and Brewing from Ballarat College, Melbourne University. She also has many honorary degrees from several renowned international universities. Ms. Mazumdar-Shaw is the aunt of our Chief Executive Officer, Dr. Claire Mazumdar. We believe Ms. Mazumdar-Shaw’s prolific experience as a pioneering biotech entrepreneur and healthcare visionary qualifies her to serve on our board of directors.
Jake Simson, Ph.D., has served as a member of our board of directors since March 2023. Since December 2020, Dr. Simson has served as a Partner of RA Capital Management, L.P., a life sciences investment advisor. Dr. Simson previously served as an associate, analyst and principal at RA Capital Management, L.P. from July 2013 to December 2020. Dr. Simson serves as a member of the board of directors of Tyra Biosciences Inc, a public biotechnology company (NASDAQ GS: TYRA) and Janux Therapeutics, Inc, a public biopharmaceutical company (NASDAQ: JANX). Dr. Simson also served on the board of directors of DICE Therapeutics, Inc., a biotechnology company (NASDAQ: DICE) or DICE, from December 2020 until it was acquired by Eli Lilly and Company in August. Dr. Simson also serves on the boards of directors of various private companies. Dr. Simson received his Ph.D. in Biomedical Engineering from Johns Hopkins University and his S.B. in Materials Science and Engineering from Massachusetts Institute of Technology. We believe Dr. Simson is qualified to serve on our board of directors due to his experience serving as a director for several private and public life science companies and his experience in the life sciences investment industry.
Ryan Cohlhepp, Pharm.D., has served as our President and Chief Operating Officer since October 2020, as a member of our board of directors from December 2020 to March 2023, and from August 2024 and onwards. Prior to Bicara, Dr. Cohlhepp was Senior Vice President R&D Strategy and Operations at Rheos Medicines, Inc., a biopharmaceutical company, from March 2018 to October 2020. Dr. Cohlhepp received a Pharm.D. from Purdue University. We believe Dr. Cohlhepp’s senior management experience in the biopharmaceutical industry make him well qualified to serve on our board of directors.
The proxies will be voted in favor of the above nominees unless a contrary specification is made in the proxy. The nominees have consented to serve as our directors if elected. However, if any nominee is unable to serve or for good cause will not serve as a director, the proxies will be voted for the election of such substitute nominee as our board of directors may designate.
Vote Required
To be elected, each director nominee must receive a plurality of the shares present in person or represented by proxy duly authorized at the meeting and entitled to vote on the election of directors, withheld votes and broker non-votes will have no effect on the election of directors.
14
Board Recommendation
The board of directors recommends voting “FOR” the election of Kiran Mazumdar-Shaw, Jake Simson, Ph.D., and Ryan Cohlhepp, Pharm.D., as the class I directors, to serve for a three-year term ending at the annual meeting of stockholders to be held in 2028.
Directors Continuing in Office
The following table identifies our continuing directors, and sets forth their principal occupation and business experience during the last five years and their ages as of April 14, 2025.
| Name | Position and Offices Held with Bicara | Director Since | Class and Year in Which Term Will Expire | Age | ||||||||||||||||||||||
Nils Lonberg, Ph.D. | Director | 2019 | Class II – 2026 | 69 | ||||||||||||||||||||||
Christopher Bowden, M.D. | Director | 2024 | Class II – 2026 | 64 | ||||||||||||||||||||||
Carolyn Ng, Ph.D. | Director | 2023 | Class II – 2026 | 41 | ||||||||||||||||||||||
Claire Mazumdar, Ph.D., M.B.A. | Chief Executive Officer and Director | 2020 | Class III – 2027 | 35 | ||||||||||||||||||||||
Kate Haviland, M.B.A | Director | 2023 | Class III – 2027 | 49 | ||||||||||||||||||||||
Scott Robertson, M.B.A. | Director | 2023 | Class III – 2027 | 45 | ||||||||||||||||||||||
Michael Powell, Ph.D. | Director | 2024 | Class III – 2027 | 70 | ||||||||||||||||||||||
Class II Directors (Term Expires at 2026 Annual Meeting)
Nils Lonberg, Ph.D., has served as a member of our board of directors since April 2019 and was previously the Chairperson of our board of directors until August 2024. Dr. Lonberg currently serves as an Executive in Residence at Canaan Partners, a venture capital firm, where he has been employed since May 2019 and where he focuses on investments in life science companies. Prior to Canaan Partners, Dr. Lonberg served as Vice President, Oncology Discovery Biology, at Bristol-Myers Squibb Co., a biopharmaceutical company, where he led drug discovery efforts for both targeted and immuno-oncology agents, from September 2009 to April 2019. Dr. Lonberg also serves on the boards of directors of various private companies. Dr. Lonberg received his Ph.D. in Biochemistry and Molecular Biology from Harvard University. He was a postdoctoral fellow at Memorial Sloan Kettering Cancer Center and was elected to the National Academy of Engineering in 2015. We believe Dr. Lonberg’s extensive executive, managerial and business experience with life sciences companies qualifies him to serve on our board of directors.
Christopher Bowden, M.D., has served as a member of our board of directors since August 2024. Since March 2023, Dr. Bowden has served as the Chief Medical Officer of Remix Therapeutics, Inc., or Remix Therapeutics, a biotechnology company. Prior to March 2023, Dr. Bowden served as a Strategic Advisor to Agios Pharmaceuticals, Inc., a biopharmaceutical company from September 2021 to March 2023. Dr. Bowden has also served as a Clinical Consultant since October 2021 for an array of biotechnology companies and venture funds, including Rivus Pharmaceutics, Inc., a pharmaceutical company from October 2021 to February 2023, Pyramid Biosciences, Inc., a biotechnology company from December 2021 to July 2022, and Remix Therapeutics from March 2022 to March 2023. Previously, he was the Chief Medical Officer of Agios Pharmaceuticals, Inc., a biopharmaceutical company, from May 2014 to September 2021. From October 2019 until March 2023, Dr. Bowden served as a member of the board of directors of Alaunos Therapeutics, Inc. (NASDAQ: TCRT), a pharmaceutical company and from August 2017 until October 2020, Dr. Bowden served as a member of the board of directors of Miragen Therapeutics, Inc., currently Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company. Dr. Bowden also serves on the boards of directors of various private companies. Dr. Bowden received his M.D. from Hahnemann University School of Medicine followed by internal medicine training at Roger Williams Medical Center and the Providence VA Medical Center, Rhode Island. He completed his medical oncology
15
fellowship at the National Cancer Institute Medicine Branch. Dr. Bowden is board certified in internal medicine and medical oncology. We believe Dr. Bowden’s extensive leadership and medical experience in the life sciences industry qualifies him to serve on our board of directors.
Carolyn Ng, Ph.D., has served as a member of our board of directors since December 2023. Dr. Ng currently serves as is a Partner and Managing Director at TPG Life Sciences Innovations, or TPG, a global investment firm, based in San Francisco, where she leads investments into transformative companies in different therapeutic areas since October 2021. Prior to joining TPG, Dr. Ng was a Managing Director at Vertex Ventures HC, a global healthcare and life sciences venture fund, where she joined in February 2015 and was promoted through various roles to be the co-Head of the investment team from June 2017 to September 2021. Dr. Ng currently serves on the board of directors of numerous private life sciences companies and previously served on the board of directors of several public companies, including Bicycle Therapeutics PLC (NASDAQ: BCYC), a biotechnology company, from June 2017 until August 2020, and Boundless Bio, Inc. (NASDAQ: BOLD), a clinical-stage oncology company, from June 2019 to September 2021. Dr. Ng holds a PhD in Cancer Molecular Biology from the National University of Singapore, where she was the recipient of the prestigious NGS, Integrative Sciences and Technology, PhD scholarship and holds a B.S. degree in Pharmacy with first class honors from the National University of Singapore. We believe Dr. Ng’s extensive experience as an investor in and a member of the board of directors of numerous life sciences companies qualifies her to serve on our board of directors.
Class III Directors (Term Expires at 2027 Annual Meeting)
Claire Mazumdar, Ph.D., M.B.A., has served as our Chief Executive Officer and as a member of our board of directors since January 2020. Prior to Bicara, Dr. Mazumdar was Head of Business Development and Corporate Strategy at Rheos Medicines, Inc. a biopharmaceutical company, from August 2017 to December 2019, which culminated in a large multi-target discovery partnership with Roche. Previously, Dr. Mazumdar was an investment professional at Third Rock Ventures, LLC, or Third Rock, a life sciences venture capital firm, from July 2017 to July 2019. Dr. Mazumdar received a BS in Biological Engineering from Massachusetts Institute of Technology, a Ph.D. in Cancer Biology from Stanford School of Medicine, and an M.B.A. from Stanford Graduate School of Business. Dr. Mazumdar is the niece of Kiran Mazumdar-Shaw, a member of our board of directors. We believe Dr. Mazumdar’s senior management experience in the biopharmaceutical industry make her well qualified to serve on our board of directors.
Kate Haviland, M.B.A., has served as a member of our board of directors since September 2023. Since April 2022, Ms. Haviland has served as the President and Chief Executive Officer of Blueprint Medicines Corporation (NASDAQ: BPMC), a public biopharmaceutical company, and previously served as the Chief Operating Officer from January 2019 to April 2022, and as the Chief Business Officer from January 2016 to January 2019. Prior to joining Blueprint, Ms. Haviland served as vice president, rare diseases and oncology program leadership at Idera Pharmaceuticals, Inc. (acquired by Aceragen, Inc.), a biopharmaceutical company, from April 2014 to December 2015, as head of commercial development at Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a public biopharmaceutical and drug development company, from June 2012 to April 2014, as executive director of commercial development at PTC Therapeutics, Inc. (NASDAQ: PTCT), a public biopharmaceutical company, from March 2007 to June 2012, and roles in corporate development and project management at Genzyme, Inc. (acquired by Sanofi, Inc. (NASDAQ: SNY), a global healthcare company) from July 2005 to April 2007. Ms. Haviland currently serves on the board of directors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a public biopharmaceutical company. Ms. Haviland holds a B.A. from Wesleyan University with a double major in Molecular Biology/Biochemistry and Economics and an M.B.A. from Harvard Business School. We believe Ms. Haviland is qualified to serve on our board of directors because she is a biotech President and Chief Executive Officer and experienced as a public company board member in the life science industry.
Scott Robertson, M.B.A., has served as a member of our board of directors since September 2023. Mr. Robertson currently serves as the Chief Financial Officer and Chief Business Officer of Star Therapeutics LLC, a biotechnology company, since January 2024. Mr. Robertson also served as the Chief Financial Officer and Chief Business Officer of DICE from July 2021 to December 2023, the Chief Financial Officer from December 2017 to July 2021, and as the Vice President, Business Development & Strategic Planning from April 2016 to December
16
2017, prior to acquisition by Eli Lilly and Company in August 2023. In addition, he currently serves as a Lecturer at the Haas School of Business at the University of California, Berkeley and previously served as a member of the board of directors of Hexima Limited (ASX: HXL), a biotechnology company, from December 2018 to September 2023. Mr. Robertson received his B.S. in Business Administration from the University of Southern California and his M.B.A. from the Haas School of Business at the University of California, Berkeley. We believe Mr. Robertson’s extensive executive and business experience with life sciences companies qualifies him to serve on our board of directors.
Michael Powell, Ph.D., has served as a member and as the Chairperson of our board of directors since August 2024. Since August 2021, Dr. Powell has served as an Executive Partner and Venture Advisor, of Omega Funds, a venture capital firm that invests in life sciences companies. Previously, he was a General Partner at Sofinnova Investments, a biopharmaceutical investment firm, from August 1997 until June 2021. Dr. Powell recently served as a member of the board of directors of Galera Therapeutics, Inc. (NASDAQ: GRTX), a biopharmaceutical company, from November 2016 to December 2024. He has also previously served as the chair and as member of the board of directors of Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI), a biopharmaceutical company, from July 2015 to May 2022. Dr. Powell has also served on the boards of directors of several private companies. Dr. Powell holds a Ph.D. in Physical Chemistry from the University of Toronto and he completed post-doctoral studies in Bioorganic Chemistry at the University of California as a National Science and Engineering Research Council Scholar. We believe Dr. Powell’s extensive experience in the life sciences investment industry qualifies him to serve on our board of directors.
17
PROPOSAL NO. 2 – RATIFICATION OF THE APPOINTMENT OF KPMG
LLP AS BICARA THERAPEUTIC’S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025
Bicara Therapeutics’ stockholders are being asked to ratify the appointment by the audit committee of the board of directors of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. KPMG LLP has served as Bicara Therapeutics’ independent registered public accounting firm since 2021.
The audit committee is solely responsible for selecting Bicara Therapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2025. Stockholder approval is not required to appoint KPMG LLP as Bicara Therapeutics’ independent registered public accounting firm. However, the board of directors believes that submitting the appointment of KPMG LLP to the stockholders for ratification is good corporate governance. If the stockholders do not ratify this appointment, the audit committee will reconsider whether to retain KPMG LLP. If the selection of KPMG LLP is ratified, the audit committee, at its discretion, may direct the appointment of a different independent registered public accounting firm at any time it decides that such a change would be in the best interest of Bicara Therapeutics and its stockholders.
A representative of KPMG LLP is expected to be present at the Annual Meeting and will have an opportunity to make a statement if he or she desires to do so and to respond to appropriate questions from our stockholders.
Principal Accountant Fees and Services
Bicara Therapeutics incurred the following fees from KPMG LLP for the audit of the consolidated financial statements and for other services related to the years ended December 31, 2024 and December 31, 2023.
| Fee Category | 2024 | 2023 | |||||||||||||||||||||
Audit Fees(1) | $ | 1,595,000 | $ | 175,000 | |||||||||||||||||||
Audit-Related Fees | — | — | |||||||||||||||||||||
Tax Fees(2) | — | — | |||||||||||||||||||||
All Other Fees | — | — | |||||||||||||||||||||
Total Fees | $ | 1,595,000 | $ | 175,000 | |||||||||||||||||||
| (1) | Audit Fees for the year ended December 31, 2024, consist of fees billed for professional services performed by KPMG for the audit of our annual consolidated financial statements, the review of interim consolidated financial statements, review of the registration statement on Form S-1 and the delivery of comfort letters for our initial public offering, review of the registration statement on Form S-8, and related services that are normally provided in connection with statutory and regulatory filings or engagements. For the year ended December 31, 2023, this category includes fees related to the annual audit. | ||||
| (2) | Tax Fees consist of fees for tax compliance, advice and tax services. There were no tax fees in fiscal years 2023 and 2024. | ||||
Audit Committee Pre-approval Policy and Procedures
Our audit committee has adopted policies and procedures relating to the approval of all audit and non-audit services that are to be performed by our independent registered public accounting firm. This policy provides that we will not engage our independent registered public accounting firm to render audit or non-audit services unless the service is specifically approved in advance by our audit committee or the engagement is entered into pursuant to the pre-approval procedure described below.
18
From time to time, our audit committee may pre-approve specified types of services that are expected to be provided to us by our independent registered public accounting firm during the next 12 months. Any such pre-approval details the particular service or type of services to be provided and is also generally subject to a maximum dollar amount.
During the fiscal years ended 2024 and 2023, no services were provided to us by KPMG LLP other than in accordance with the pre-approval policies and procedures described above.
Vote Required
To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025, the affirmative vote of a majority of the votes properly cast for and against this Proposal No. 2 is required. Abstentions will have no effect on the outcome of this proposal. This proposal is considered to be a discretionary item, and your broker will be able to vote on this proposal even if it does not receive instructions from you. Accordingly, we do not anticipate that there will be any broker non-votes on this proposal; however, any broker non-votes will not be counted as “votes cast” and will therefore have no effect on this proposal.
Board Recommendation
The board of directors recommends voting “FOR” Proposal No. 2 to ratify the appointment of KPMG LLP as Bicara Therapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2025.
19
CORPORATE GOVERNANCE
Director Nomination Process
Our nominating and corporate governance committee is responsible for identifying individuals qualified to serve as directors, consistent with criteria approved by our board, and recommending such persons to be nominated for election as directors, except where we are legally required by contract, law or otherwise to provide third parties with the right to nominate.
The process followed by our nominating and corporate governance committee to identify and evaluate director candidates includes requests to board members and others for recommendations, meetings from time to time to evaluate biographical information and background material relating to potential candidates, and interviews of selected candidates by management, recruiters, members of the committee and our board. The qualifications, qualities and skills that our nominating and corporate governance committee believes must be met by a committee recommended nominee for a position on our board of directors are as follows:
•Nominees should demonstrate high standards of personal and professional ethics and integrity.
•Nominees should have proven achievement and competence in the nominee’s field and the ability to exercise sound business judgment.
•Nominees should have the education, expertise and business acumen to make significant contributions to the Company’s success.
•Nominees should have skills that are complementary to those of the existing board.
•Nominees should have the ability to assist and support management and make significant contributions to the Company’s success.
•Nominees should have an understanding of the fiduciary responsibilities that are required of a member of the board of directors and the commitment of time and energy necessary to diligently carry out those responsibilities.
•Nominees should have a diverse personal background, perspective and experience.
•Nominees should have a commitment to vigorously represent the long-term interests of our stockholders.
Stockholders may recommend individuals to the nominating and corporate governance committee for consideration as potential director candidates. Any such proposals should be submitted to our corporate secretary at our principal executive offices no later than the close of business on the 90th day nor earlier than the close of business on the 120th day prior to the one-year anniversary of the date of the preceding year’s annual meeting and should include appropriate biographical and background material to allow the nominating and corporate governance committee to properly evaluate the potential director candidate and the number of shares of our stock beneficially owned by the stockholder proposing the candidate. Stockholder proposals should be addressed to Bicara Therapeutics Inc., 116 Huntington Avenue, Suite 703, Boston, MA 02116, Attention: Corporate Secretary. Assuming that biographical and background material has been provided on a timely basis in accordance with our bylaws, any recommendations received from stockholders will be evaluated in the same manner as potential nominees proposed by the nominating and corporate governance committee. If our board of directors determines to nominate a stockholder recommended candidate and recommends his or her election, then his or her name will be included on our proxy card for the next annual meeting of stockholders. See “Stockholder Proposals” for a discussion of submitting stockholder proposals.
Director Independence
Applicable Nasdaq Stock Market LLC, or Nasdaq, rules require a majority of a listed company’s board of directors to be comprised of independent directors within one year of listing. In addition, the Nasdaq rules require that, subject to specified exceptions, each member of a listed company’s audit, compensation and nominating and corporate governance committees be independent and that audit committee members also satisfy independence criteria set forth in Rule 10A-3 under the Exchange Act and that compensation committee members satisfy
20
independence criteria set forth in Rule 10C-1 under the Exchange Act. Under applicable Nasdaq rules, a director will only qualify as an “independent director” if, in the opinion of the listed company’s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. In addition, in affirmatively determining the independence of any director who will serve on a company’s compensation committee, Rule 10C-1 under the Exchange Act requires that a company’s board of directors must consider all factors specifically relevant to determining whether a director has a relationship to such company which is material to that director’s ability to be independent from management in connection with the duties of a compensation committee member, including: the source of compensation to the director, including any consulting, advisory or other compensatory fee paid by such company to the director, and whether the director is affiliated with the company or any of its subsidiaries or affiliates.
Our board of directors has determined that all members of the board of directors, except Claire Mazumdar Ph.D., and Ryan Cohlhepp Pharm.D. are independent directors, including for purposes of the rules of Nasdaq and the SEC. In making such independence determination, our board of directors considered the relationships that each non-employee director has with us and all other facts and circumstances that our board of directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each non-employee director. In considering the independence of the directors listed above, our board of directors considered the association of our directors with the holders of more than 5% of our common stock. Dr. Mazumdar is the niece of Ms. Mazumdar-Shaw, otherwise, there are no family relationships among any of our directors or executive officers. Dr. Mazumdar is not an independent director under these rules because she is the Chief Executive Officer of the Company. Dr. Cohlhepp is not an independent director under these rules because he is the President and Chief Operating Officer of the Company.
Board Committees
Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee. Each of the audit committee, compensation committee and nominating and corporate governance committee operates under a charter that satisfies the applicable standards of the SEC and Nasdaq. Each such committee reviews its respective charter at least annually. A current copy of the charter for each of the audit committee, compensation committee and nominating and corporate governance committee is posted on the corporate governance section of our website https://ir.bicara.com/corporate-governance/governance-overview.
Audit Committee
Michael Powell, Carolyn Ng, and Scott Robertson serve on the audit committee, which is chaired by Scott Robertson. Our board of directors has determined that each member of the audit committee is “independent” for audit committee purposes as that term is defined by the rules of the SEC and Nasdaq, and that each has sufficient knowledge in financial and auditing matters to serve on the audit committee. Our board of directors has designated Scott Robertson as an “audit committee financial expert,” as defined under the applicable rules of the SEC. During the fiscal year ended December 31, 2024, the audit committee met two times. The audit committee’s responsibilities include:
•appointing, approving the compensation of, and assessing the independence of our independent registered public accounting firm;
•pre-approving auditing and permissible non-audit services, and the terms of such services, to be provided by our independent registered public accounting firm;
•reviewing the overall audit plan with our independent registered public accounting firm and members of management responsible for preparing our financial statements;
21
•reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly financial statements and related disclosures as well as critical accounting policies and practices used by us;
•coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;
•establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns;
•recommending, based upon the audit committee’s review and discussions with management and our independent registered public accounting firm, whether our audited financial statements shall be included in our Annual Report on Form 10-K;
•monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they relate to our financial statements and accounting matters;
•reviewing and discussing with management and our board of directors our cybersecurity risks, including information security and technology risks;
•preparing the audit committee report required by SEC rules to be included in our annual proxy statement;
•reviewing all related person transactions for potential conflict of interest situations and approving all such transactions;
•reviewing quarterly earnings releases; and
•reviewing our major risk exposures, including financial, operational, cybersecurity, competition, legal and regulatory exposures.
All audit and non-audit services, other than de minimis non-audit services, to be provided to us by our independent registered public accounting firm must be approved in advance by our audit committee.
Compensation Committee
Michael Powell, Christopher Bowden, and Kate Haviland serve on the compensation committee, which is chaired by Michael Powell. Our board of directors has determined that each member of the compensation committee is “independent” as defined in the applicable Nasdaq rules. During the fiscal year ended December 31, 2024, the compensation committee met three times. The compensation committee’s responsibilities include:
•reviewing and recommending to the board of directors the corporate goals and objectives relevant to the compensation of our Chief Executive Officer and President;
•evaluating the performance of our Chief Executive Officer and President in light of such corporate goals and objectives and based on such evaluation: (i) recommending to the board of directors the cash compensation of our Chief Executive Officer and President, and (ii) recommending to the board of directors grants and awards to our Chief Executive Officer and President under equity-based plans;
•reviewing and approving the cash compensation of our other executive officers;
•reviewing and establishing our overall management compensation, philosophy and policy;
•overseeing and administering our compensation and similar plans;
•reviewing and approving the retention or termination of any consulting firm or outside advisor to assist in the evaluation of compensation matters and evaluating and assessing potential and current compensation advisors in accordance with the independence standards identified in the applicable Nasdaq rules;
•retaining and approving the compensation of any compensation advisors;
•reviewing and recommending to the board of directors our policies and procedures for the grant of equity-based awards;
•reviewing and recommending to the board of directors the compensation of our directors; and
•reviewing and approving the compensation committee report required by SEC rules, if and when required, to be included in our annual proxy statement.
The compensation committee may establish and delegate authority to one or more subcommittees consisting of one or more of its members to carry out its responsibilities. For example, to the extent permitted
22
by applicable law and the provisions of a given equity-based plan, the compensation committee may delegate to a committee consisting one or more executive officers of the Company the power to grant stock awards, and amend the terms of such awards, pursuant to such equity-based plan to employees of the Company or any subsidiary of the Company who are not directors or executive officers of the Company, such power to be subject to the parameters and limitations set forth in the applicable resolutions adopted by the compensation committee. Additionally, to the extent permitted by applicable law and the provisions of any employee benefit plan, the compensation committee may delegate any of its duties, responsibilities or authority in connection with any employee benefit plan to members of management as the compensation committee deems appropriate.
Nominating and Corporate Governance Committee
Nils Lonberg, Jake Simson and Kiran Mazumdar-Shaw serve on the nominating and corporate governance committee, which is chaired by Nils Lonberg. Our board of directors has determined that each member of the nominating and corporate governance committee is “independent” as defined in the applicable Nasdaq rules. During the fiscal year ended December 31, 2024, the nominating and corporate governance committee met one time. The nominating and corporate governance committee’s responsibilities include:
•developing and recommending to the board of directors criteria for board and committee membership;
•establishing procedures for identifying and evaluating board of director candidates, including nominees recommended by stockholders;
•reviewing the composition of the board of directors to ensure that it is composed of members containing the appropriate skills and expertise to advise us;
•identifying individuals qualified to become members of the board of directors;
•recommending to the board of directors the persons to be nominated for election as directors and to each of the board’s committees;
•reviewing and recommending to the board of directors appropriate corporate governance guidelines; and
•overseeing the evaluation of our board of directors.
The nominating and corporate governance committee considers candidates for board of directors membership suggested by its members and the Chief Executive Officer. Additionally, in selecting nominees for directors, the nominating and corporate governance committee will review candidates recommended by stockholders in the same manner and using the same general criteria as candidates recruited by the committee and/or recommended by our board of directors. Any stockholder who wishes to recommend a candidate for consideration by the committee as a nominee for director should follow the procedures described later in this proxy statement under the heading “Stockholder Proposals.” The nominating and corporate governance committee will also consider whether to nominate any person proposed by a stockholder in accordance with the provisions of our bylaws relating to stockholder nominations as described later in this proxy statement under the heading “Stockholder Proposals.”
Identifying and Evaluating Director Nominees. Our board of directors is responsible for filling vacancies on our board of directors and for nominating candidates for election by our stockholders each year in the class of directors whose term expires at the relevant annual meeting. The board of directors delegates the selection and nomination process to the nominating and corporate governance committee, with the expectation that other members of the board of directors, and of management, will be requested to take part in the process as appropriate.
Generally, the nominating and corporate governance committee identifies candidates for director nominees in consultation with management, through the use of search firms or other advisors, through the recommendations submitted by stockholders or through such other methods as the nominating and corporate governance committee deems to be helpful to identify candidates. Once candidates have been identified, the nominating and corporate governance committee confirms that the candidates meet all of the minimum qualifications for director nominees established by the nominating and corporate governance committee. The nominating and corporate governance committee may gather information about the candidates through interviews, detailed questionnaires, comprehensive
23
background checks or any other means that the nominating and corporate governance committee deems to be appropriate in the evaluation process. The nominating and corporate governance committee then meets as a group to discuss and evaluate the qualities and skills of each candidate, both on an individual basis and taking into account the overall composition and needs of our board of directors. Based on the results of the evaluation process, the nominating and corporate governance committee recommends candidates for the board of directors’ approval to fill a vacancy or as director nominees for election to the board of directors by our stockholders each year in the class of directors whose term expires at the relevant annual meeting.
Board Diversity Policies
Our Corporate Governance Guidelines provide that the value of diversity should be considered in determining director candidates as well as other factors such as a candidate’s character, judgment, skills, education, expertise and absence of conflicts of interest. Our priority in selection of board members is the identification of members who will further the interests of our stockholders through their established records of professional accomplishment, their ability to contribute positively to the collaborative culture among board members, and their knowledge of our business and understanding of the competitive landscape in which we operate and adherence to high ethical standards. The nominating and corporate governance committee and the full board of directors are committed to creating a board of directors with diversity, including diversity of expertise, experience, ethnicity, race, background and gender, and are committed to identifying, recruiting and advancing candidates offering such diversity in future searches.
Board and Committee Meetings Attendance
The full board of directors met six times during 2024. During 2024, each member of the board of directors, except for Kiran Mazumdar-Shaw, attended in person or participated in 75% or more of the aggregate of (i) the total number of meetings of the board of directors (held during the period for which such person has been a director), and (ii) the total number of meetings held by all committees of the board of directors on which such person served (during the periods that such person served).
Director Attendance at Annual Meeting of Stockholders
Directors are responsible for attending the annual meeting of stockholders to the extent practicable.
Policy on Trading, Pledging and Hedging of Company Stock
Certain transactions in our securities (such as purchases and sales of publicly traded put and call options, and short sales) create a heightened compliance risk or could create the appearance of misalignment between management and stockholders. In addition, securities held in a margin account or pledged as collateral may be sold without consent if the owner fails to meet a margin call or defaults on the loan, thus creating the risk that a sale may occur at a time when an officer or director is aware of material, non-public information or otherwise is not permitted to trade in Company securities. Our insider trading policy expressly prohibits derivative transactions of our stock by our executive officers, directors and employees. Our insider trading policy expressly prohibits purchases of any derivative securities that provide the economic equivalent of ownership.
Rule 10b5-1 Trading Plan Policy
We have adopted a Rule 10b5-1 trading plan policy, which permits our officers, directors, employees and certain other persons to enter into trading plans complying with Rule 10b5-1 under the Exchange Act. Generally, under these trading plans, the individual relinquishes control over the transactions once the trading plan is put into place and can only put such plans into place while the individual is not in possession of material non-public information. Accordingly, sales under these plans may occur at any time, including possibly before, simultaneously with, or immediately after significant events involving our company.
24
Insider Trading Policy
We have adopted an insider trading policy which governs transactions in our securities by the Company and its directors, officers, employees, and consultants and is designed to promote compliance with insider trading laws, rules and regulations applicable to the Company. A copy of our insider trading policy is filed with our Annual Report on Form 10-K as Exhibit 19.1.
Compensation Recovery Policy
In accordance with the requirements of the SEC and Nasdaq listing rules, we maintain a compensation recovery policy, or clawback policy. The clawback policy provides that in the event we are required to prepare a restatement of financial statements due to material noncompliance with any financial reporting requirement under securities laws, we must (subject to certain limited exceptions described in the clawback policy and permitted under the SEC and Nasdaq listing rules) recover any incentive-based compensation that was based upon the attainment of a financial reporting measure and that was received by any current or former executive officer during the three-year period preceding the date that the restatement was required if such compensation exceeds the amount that the executive officer would have received based on the restated financial statements. A copy of our compensation recovery policy was filed with our Registration Statement on Form S-1 as Exhibit 10.8.
Policies and Practices Related to the Grant of Certain Equity Awards
We generally grant equity awards on a regularly scheduled basis in accordance with our equity award grant policy . Any annual equity awards to eligible employees, including our executive officers, will be effective upon the first trading day of the month following approval of such awards, which approval will generally occur at the regularly-scheduled meeting of our board of directors or our compensation committee (as applicable). Annual awards to members of our board of directors will be made on the date of our annual meeting of stockholders, initial awards to members of our board of directors will be made on the date of their election or appointment, as applicable, and awards to new hires or in connection with a promotion will be made on a regular basis and shall become effective on the first trading day of the month following the later of approval of the award or the employee’s date of hire or promotion, as applicable.
During 2024, we did not grant any stock options, stock appreciation rights or similar option-like instruments to any of our named executive officers during any period beginning four business days before and ending one business day after the filing or furnishing of a Form 10-Q, Form 10-K or Form 8-K that discloses material non-public information.
Code of Business Conduct and Ethics
We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of the code is posted on the corporate governance section of our website, which is located at https://ir.bicara.com/corporate-governance/governance-overview. If we make any substantive amendments to, or grant any waivers from, the code of business conduct and ethics for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form 8-K.
Board Leadership Structure and Board’s Role in Risk Oversight
25
Currently, the role of chairperson of the board of directors is separated from the role of Chief Executive Officer. Our Chief Executive Officer is responsible for recommending strategic decisions and capital allocation to the board of directors and to ensure the execution of the recommended plans. Michael Powell is our current chairperson of the board of directors. The chairperson of the board of directors is responsible for leading the board of directors in its fundamental role of providing advice to and independent oversight of management. Our board of directors recognizes the time, effort and energy that the Chief Executive Officer is required to devote to her position in the current business environment, as well as the commitment required to serve as our chairperson, particularly as the board of directors’ oversight responsibilities continue to grow. While our amended and restated bylaws and corporate governance guidelines will not require that our chairperson and Chief Executive Officer positions be separate, our board of directors believes that having separate positions is the appropriate leadership structure for us at this time and demonstrates our commitment to good corporate governance.
Risk is inherent to every business, and how well a business manages risk can ultimately determine its success. We face a number of risks, including risks relating to our financial condition, development and commercialization activities, operations, strategic direction and intellectual property. Management is responsible for the day-to-day management of risks we face, while our board of directors, as a whole and through its committees, has responsibility for the oversight of risk management. In its risk oversight role, our board of directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are adequate and functioning as designed.
The role of the board of directors in overseeing the management of our risks is conducted primarily through committees of the board of directors, as disclosed in the descriptions of each of the committees below and in the charters of each of the committees. The full board of directors (or the appropriate board committee in the case of risks that are under the purview of a particular committee) discusses with management our major risk exposures, their potential impact on us, and the steps we take to manage them. When a board committee is responsible for evaluating and overseeing the management of a particular risk or risks, the chairperson of the relevant committee reports on the discussion to the full board of directors during the committee reports portion of the next board meeting. This enables the board of directors and its committees to coordinate the risk oversight role, particularly with respect to risk interrelationships.
Communication with the Directors of Bicara Therapeutics
Any interested party with concerns about our company may report such concerns to the board of directors or the Chairperson of our board of directors and nominating and corporate governance committee, by submitting a written communication to the attention of such director at the following address:
c/o Bicara Therapeutics Inc.
116 Huntington Avenue, Suite 703
Boston, MA 02116
United States
You may submit your concern anonymously or confidentially by postal mail. You may also indicate whether you are a stockholder, customer, supplier or other interested party.
A copy of any such written communication may also be forwarded to our legal counsel and a copy of such communication may be retained for a reasonable period of time. The director may discuss the matter with our legal counsel, with independent advisors, with non-management directors, or our management, or may take other action or no action as the director determines in good faith, using reasonable judgment and applying his or her own discretion.
Communications may be forwarded to other directors if they relate to important substantive matters and include suggestions or comments that may be important for other directors to know. In general, communications relating to corporate governance and long-term corporate strategy are more likely to be forwarded than
26
communications relating to ordinary business affairs, personal grievances and matters as to which we tend to receive repetitive or duplicative communications.
The audit committee oversees the procedures for the receipt, retention, and treatment of complaints received by Bicara Therapeutics regarding accounting, internal accounting controls, or audit matters, and the confidential, anonymous submission by employees of concerns regarding questionable accounting, internal accounting controls or auditing matters. We have also established a toll-free telephone number for the reporting of such activity, which is (833) 805-1103, which permits submissions on a confidential and anonymous basis.
Executive Officers Who Are Not Directors
The following table identifies our executive officers who are not directors, and sets forth their current positions at Bicara Therapeutics and their ages as of April 14, 2025.
| Name | Position Held with Bicara | Officer Since | Age | |||||||||||||||||||||||
Ivan Hyep, M.B.A | Chief Financial Officer | 2021 | 40 | |||||||||||||||||||||||
David Raben, M.D. | Chief Medical Officer | 2023 | 61 | |||||||||||||||||||||||
Lara Meisner, J.D. | Chief Legal Officer | 2023 | 53 | |||||||||||||||||||||||
Ivan Hyep, M.B.A., has served as our Chief Financial Officer since March 2021. Prior to joining Bicara, Mr. Hyep was the Director of Finance of MOMA Therapeutics, Inc., a biotechnology company, from July 2019 to March 2021. Previously, Mr. Hyep was an investment professional at Third Rock, a life sciences venture capital firm, from January 2016 to March 2021. Prior to that, Mr. Hyep was a Financing Manager at Bain Capital, LP, a private investment firm, from July 2006 to January 2016. Mr. Hyep holds a BS in Finance from Bentley University and received his M.B.A. from Boston University.
David Raben, M.D., has served as our Chief Medical Officer since July 2023, having consulted for us from May 2023 to July 2023. Previously, Dr. Raben was Vice President of late-stage product development at Amgen Inc., a biotechnology company, from November 2021 to May 2023, where he led the recently FDA-approved Tarlatamab program for SCLC. Before that, he was Vice President of late-stage product development for lung, skin, head and neck cancer (HNC) at Genentech, Inc., a biotechnology company, from September 2019 to June 2021. He also served as a Professor of Radiation Oncology at the University of Colorado Health from May 1998 to September 2019. Dr. Raben is a board-certified radiation oncologist with a career focused on investigating novel biologic strategies against growth factor signaling and immunosuppression for patients advanced lung and HNC. He earned a BA in Psychology from Duke University in 1985, an M.D. from the Bowman Gray School of Medicine at Wake Forest University in 1990 and completed his residency at the Johns Hopkins Hospital in 1994.
Lara S. Meisner, J.D., has served as our Chief Legal Officer since November 2023 and Corporate Secretary since December 2023. Prior to joining Bicara, Ms. Meisner served as the Chief Legal Officer, Compliance Officer, and Corporate Secretary at Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company, from December 2020 to November 2023. From February 2017 to November 2020, Ms. Meisner held roles of increasing responsibility at Catabasis Pharmaceuticals, Inc. (now Astria Therapeutics, Inc. (NASDAQ: ATXS)), a biopharmaceutical company, most recently as the VP, Legal, and Corporate Secretary. Ms. Meisner received her J.D. from Temple University Beasley School of Law and her BA from the University of Michigan.
The principal occupation and employment during the past five years of each of our executive officers was carried on, in each case except as specifically identified in this proxy statement, with a corporation or organization that is not a parent, subsidiary or other affiliate of us. There is no arrangement or understanding between any of our executive officers and any other person or persons pursuant to which he or she was or is to be selected as an executive officer.
There are no material legal proceedings to which any of our directors, executive officers, or affiliates is a party adverse to us or our subsidiary or in which any such person has a material interest adverse to us or our subsidiary.
27
Director Compensation
The table below shows all compensation earned by or paid to our non-employee directors during 2024. Other than as set forth below, we did not pay any compensation, make any equity awards or non-equity awards to, or pay any other compensation to any of the non-employee members of our board of directors in 2024. Claire Mazumdar, Ph.D., M.B.A., our Chief Executive Officer, and Ryan Cohlhepp, Pharm.D., our President and Chief Operating Officer, served as members of our board of directors and received no additional compensation for their services as members of our board of directors and, consequently, are not included in this table. The compensation received by Dr. Mazumdar and Dr. Cohlhepp during 2024 is set forth in the section of this proxy statement captioned “Executive Compensation —2024 Summary Compensation Table.”
| Name | Fees Earned or Paid in Cash ($)(1) | Option Awards($)(2) | Total ($) | |||||||||||||||||
Christopher Bowden, M.D. (3) | 18,098 | 421,685 | 439,783 | |||||||||||||||||
Kate Haviland, M.B.A. (4) | 41,603 | 319,749 | 361,352 | |||||||||||||||||
Vijay Kuchroo, D.V.M., Ph.D. (5) | 30,652 | — | 30,652 | |||||||||||||||||
Nils Lonberg, Ph.D. (6) | 45,000 | 319,749 | 364,749 | |||||||||||||||||
Heath Lukatch, Ph. D. (7) | — | — | — | |||||||||||||||||
Kiran Mazumdar-Shaw (8) | 13,152 | 319,749 | 332,901 | |||||||||||||||||
Carolyn Ng, Ph.D. (9) | — | — | — | |||||||||||||||||
Ketan Patel, M.D., M.B.A. (10) | — | — | — | |||||||||||||||||
Michael Powell, Ph.D. (11) | 35,190 | 421,685 | 456,875 | |||||||||||||||||
Scott Robertson, M.B.A. (12) | 44,592 | 319,749 | 364,341 | |||||||||||||||||
Jake Simson, Ph.D. (13) | 13,152 | 319,749 | 332,901 | |||||||||||||||||
28
| (1) | The amounts reported represent the cash fees each director received for their services to our board of directors during the year ended December 31, 2024. | ||||
| (2) | The amounts reported represent the aggregate grant date fair value of the stock option awards granted to our directors during 2024, calculated in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or FASB ASC Topic 718. Such grant date fair values do not take into account any estimated forfeitures related to service-based vesting. A discussion of the assumptions used in determining grant date fair value may be found in Note 10 to our financial statements in our 2024 Annual Report. The amounts reported in this column reflect the accounting cost for these stock option awards and do not correspond to the actual economic value that may be received by our directors upon the exercise of the stock option awards or any sale of the underlying shares. | ||||
| (3) | As of December 31, 2024, Dr. Bowden held outstanding options to purchase an aggregate of 59,501 shares of our common stock. Dr. Bowden joined our board of directors effective August 15, 2024. | ||||
| (4) | As of December 31, 2024, Ms. Haviland held outstanding options to purchase an aggregate of 75,809 shares of our common stock. | ||||
| (5) | As of December 31, 2024, Dr. Kuchroo did not hold outstanding options to purchase shares of our common stock. Dr. Kuchroo resigned from our board of directors effective September 12, 2024. | ||||
| (6) | As of December 31, 2024, Dr. Lonberg held outstanding options to purchase an aggregate of 62,030 shares of our common stock. | ||||
| (7) | As of December 31, 2024, Dr. Lukatch did not hold outstanding options to purchase shares of our common stock. Dr. Lukatch resigned from our board of directors effective September 12, 2024. | ||||
| (8) | As of December 31, 2024, Ms. Mazumdar-Shaw held outstanding options to purchase an aggregate of 32,080 shares of our common stock. | ||||
| (9) | As of December 31, 2024, Dr. Ng did not hold outstanding options to purchase shares of our common stock. Dr. Ng has waived her right to participate in our non-employee director compensation program due to her affiliation with TPG Life Sciences Innovations (“TPG LSI”) and its affiliated funds, and accordingly, does not receive any stock options or cash fees for her services as a member of our board. | ||||
| (10) | As of December 31, 2024, Dr. Patel did not hold outstanding options to purchase shares of our common stock. Dr. Patel resigned from our board of directors effective August 21, 2024. | ||||
| (11) | As of December 31, 2024, Dr. Powell held outstanding options to purchase an aggregate of 59,501 shares of our common stock. Dr. Powell joined our board of directors effective August 15, 2024. | ||||
| (12) | As of December 31, 2024, Mr. Robertson held outstanding options to purchase an aggregate of 83,247 shares of our common stock . | ||||
| (13) | As of December 31, 2024, Dr. Simson held outstanding options to purchase an aggregate of 23,746 shares of our common stock. Dr. Simson is affiliated with RA Capital Management L.P. and pursuant to the internal policies of RA Capital Management L.P., Dr. Simson holds these stock options as a nominee on behalf, and for the sole benefit, of RA Capital Management L.P. and has disclaimed beneficial ownership over these options and the underlying shares of common stock. | ||||
In September 2024, in connection with our initial public offering, or IPO, our board of directors approved option grants to certain members of our board of directors, with each of Ms. Haviland, Dr. Lonberg, Ms. Mazumdar-Shaw, Mr. Robertson, and Dr. Simson being granted an option to purchase 23,746 shares of our common stock under our 2024 Plan with an exercise price per share equal to the fair market value of a share of our common stock on the grant date of the option. Subject to the applicable directors’ continued service relationship with us, the options will vest in full and become exercisable on the earlier of (i) our 2025 annual meeting of stockholders or (ii) the one-year anniversary of the grant. Such option grants will become fully vested and exercisable upon a sale of the Company.
Furthermore, in August 2024, our board of directors adopted the non-employee director compensation policy that became effective upon our IPO in September 2024, that is designed to enable us to attract and retain, on a long-term basis, highly qualified non-employee directors. Under the policy, we pay our non-employee directors a cash retainer for service on the board of directors and for service on each committee on which the director is a member. The chairman of each committee receives a higher retainer for such service. The cash retainers paid to non-employee directors for service on the board of directors and for service on each committee of the board of directors on which the director is a member pursuant to the non-employee director compensation policy are as follows (which will be payable quarterly in arrears and prorated for partial years of service):
29
| Annual Retainer | ||||||||
| Board of Directors: | ||||||||
| Members | $ | 40,000 | ||||||
| Additional retainer for non-executive chair | $ | 30,000 | ||||||
| Additional retainer for lead independent director | $ | 20,000 | ||||||
| Additional Annual Retainer for Committee Membership: | ||||||||
| Audit Committee: | ||||||||
| Members (other than chair) | $ | 7,500 | ||||||
| Chair | $ | 15,000 | ||||||
| Compensation Committee: | ||||||||
| Members (other than chair) | $ | 5,000 | ||||||
| Chair | $ | 10,000 | ||||||
| Nominating and Corporate Governance Committee: | ||||||||
| Members (other than chair) | $ | 4,000 | ||||||
| Chair | $ | 8,000 | ||||||
The non-employee director compensation policy provides that, upon initial election or appointment to our board of directors, each non-employee director will be granted a one-time stock option award to purchase 47,492 shares of our common stock, or Initial Award. The Initial Award will vest over three years from the grant date, with one-third vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments thereafter, subject to continued service through the applicable vesting date. The Initial Award will expire ten years from the date of grant and have an exercise price per share equal to the fair market value of our common stock on the date of grant.
Furthermore, on the date of each annual meeting of stockholders, each non-employee director (other than a director receiving an Initial Award) who continues as a non-employee director following such meeting will be granted an annual stock option award to purchase 23,746 shares of our common stock, or Annual Award. The Annual Award will vest on the earlier of (i) the one-year anniversary of the grant date or (ii) the next Annual Meeting of Stockholders, subject to continued service through the applicable vesting date. The Annual Award will expire ten years from the date of grant and have an exercise price per share equal to the fair market value of our common stock on the date of grant. Following the IPO, if a non-employee director joins the board of directors on a date other than the date of our Annual Meeting of Stockholders, then, at the next Annual Meeting of Stockholders, in lieu of the Annual Award, such director will be granted a pro-rata portion of the Annual Award based on the number of full months between such director’s initial election or appointment and the such Annual Meeting of Stockholders.
The Initial Award and the Annual Award are subject to full accelerated vesting upon the sale of the Company.
The aggregate amount of compensation, including both equity compensation and cash compensation, paid to any non-employee director for service as a non-employee director in a calendar year period will not exceed $1,000,000 in the first calendar year such individual becomes a non-employee director and $750,000 in any other calendar year.
We will reimburse all reasonable out-of-pocket expenses incurred by directors for their attendance at meetings of our board of directors or any committee thereof.
30
Executive Compensation
This section describes the material elements of compensation awarded to, earned by or paid to our named executive officers in 2024, who were Claire Mazumdar, Ph.D., M.B.A., our Chief Executive Officer, Ryan Cohlhepp, Pharm.D., our president and Chief Operating Officer and Ivan Hyep, M.B.A, our Chief Financial Officer. These individuals represent our principal executive officer and our two most highly compensated executive officers (other than our principal executive officer) who were serving as executive officers on December 31, 2024. We are an “emerging growth company,” within the meaning of the JOBS Act, and have elected to comply with the reduced compensation disclosure requirements available to emerging growth companies under the JOBS Act. This section also provides qualitative information regarding the manner and context in which compensation is awarded to and earned by our named executive officers and is intended to place in perspective the data presented in the tables and narrative that follow.
2024 Summary Compensation Table
The following table presents the compensation awarded to, earned by or paid to each of our named executive officers for services rendered to us in all capacities during the years indicated.
| Name and Principal Position | Year | Salary ($) | Bonus ($) | Option Awards ($)(1) | Non-Equity Incentive Plan Compensation ($)(2) | All Other Compensation ($) | Total ($) | ||||||||||||||||
Claire Mazumdar, Ph.D. M.B.A. Chief Executive Officer | 2024 | 517,500 | 287,000(3) | 8,088,723 | 10,000 | 15,300(4) | 8,918,523 | ||||||||||||||||
| 2023 | 450,000 | 180,000 | 3,893,323 | 20,000 | — | 4,543,323 | |||||||||||||||||
Ryan Cohlhepp, Pharm.D. President and Chief Operating Officer | 2024 | 517,500 | 278,000(3) | 3,641,839 | 10,000 | 20,250(4) | 4,467,589 | ||||||||||||||||
| 2023 | 450,000 | 190,000 | 2,498,786 | 20,000 | — | 3,158,786 | |||||||||||||||||
Ivan Hyep, M.B.A Chief Financial Officer | 2024 | 438,125 | 457,000(3) | 2,683,461 | — | 20,250(4) | 3,598,836 | ||||||||||||||||
| 2023 | 350,000 | 247,500 | 1,883,243 | — | — | 2,480,743 | |||||||||||||||||
| (1) | The amounts reported represent the aggregate grant date fair value of stock option awards granted to our named executive officers during our fiscal years ended December 31, 2024 and December 31, 2023, as applicable, computed in accordance with FASB ASC Topic 718. Such grant date fair values do not take into account any estimated forfeitures related to service-based vesting. A discussion of the assumptions used in determining grant date fair value may be found in Note 10 to our financial statements in our Annual Report on Form 10-K for the year ended December 31, 2024. These amounts do not correspond to the actual value that may be recognized by the named executive officers upon exercise of the applicable award or sale of the underlying shares of stock. | ||||
| (2) | The amounts reported represent milestone bonuses earned in connection with the Company's achievement of certain clinical development goals, as described below under “2024 Cash Incentive Compensation”. | ||||
| (3) | The amounts reported represent annual cash incentive bonuses earned by our named executive officers for performance during our fiscal years ended December 31, 2024 ($287,000, $278,000 and $202,000 for Dr. Mazumdar, Dr. Cohlhepp and Mr. Hyep, respectively), which were paid in the first quarter of 2025. In the case of Mr. Hyep, the amount reported also includes a retention bonus in an amount of $250,000 and referral bonus in an amount of $5,000. For more information on these bonuses, see the description of the cash incentive bonuses under “Cash Bonuses” below. | ||||
| (4) | The amounts reported represent employer profit sharing contributions and employer matching contributions earned by our named executive officers under our 401(k) plan during our fiscal year ended December 31, 2024. | ||||
31
Narrative to Summary Compensation Table
Our board of directors and compensation committee review compensation annually for our executives. In setting executive base salaries and bonuses and granting equity incentive awards, we consider compensation for comparable positions in the market, the historical compensation at Bicara of our executives, individual performance as compared to our expectations and objectives, our desire to motivate our employees to achieve short- and long-term results that are in the best interests of our stockholders, and a long-term commitment to our Company. We target a general competitive position, based on independent third-party benchmark analytics to inform the mix of compensation of base salary, bonus and long-term incentives.
Our compensation committee is primarily responsible for determining the compensation for our executive officers. Our compensation committee typically reviews and discusses management’s proposed compensation with our Chief Executive Officer for all executives other than the Chief Executive Officer. Based on those discussions and its discretion, taking into account the factors noted above, the compensation committee then sets the compensation for each executive officer other than the Chief Executive Officer and recommends the compensation for the Chief Executive Officer to our board of directors for approval. Our board of directors discusses the compensation committee’s recommendation and ultimately approves the compensation of our Chief Executive Officer without members of management present. Our compensation committee may delegate certain authorities to a subcommittee comprised of one or more members of the board of directors or one or more officers of the Company, including our Chief Executive Officer, and has delegated to our Chief Executive Officer the authority to make certain equity award grants to employees (other than our executive officers), within specified limits approved by the compensation committee.
Our compensation committee has the authority to engage the services of a consulting firm or other outside advisor to assist it in designing our executive compensation programs and in making compensation decisions. During 2024, the compensation committee retained the services of Pearl Meyer as its external compensation consultant to advise on executive and director compensation matters including our overall compensation program design and collection of market data to inform our compensation programs for our executive officers and members of our board of directors. During 2024, Pearl Meyer did not provide any additional services besides advising the compensation committee on compensation matters. Pearl Meyer reports directly to our compensation committee. Our compensation committee annually assesses its independence consistent with Nasdaq listing standards and concluded that the engagement of such consultant did not raise any conflict of interest.
2024 Base Salaries
Our named executive officers each receive a base salary to compensate them for services rendered to our Company. The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive’s skill set, experience, role and responsibilities. Base salaries are reviewed annually, typically in connection with our annual performance review process, approved by our board of directors or the compensation committee of the board of directors, and may be adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities, performance and experience.
The annual base salaries for each of our named executive officers for the fiscal year ended December 31, 2024 are set forth in the table below:
32
| Name | Annual Base Salary from January 1, 2024 through September 15, 2024 | Annual Base Salary from September 16, 2024 through December 31, 2024* | ||||||||||||
Claire Mazumdar, Ph.D., M.B.A. | $ | 500,000 | 560,000 | |||||||||||
Ryan Cohlhepp, Pharm.D. | $ | 500,000 | 560,000 | |||||||||||
Ivan Hyep, M.B.A. | $ | 425,000 | 470,000 | |||||||||||
* Annual base salaries were increased in connection with our IPO.
2024 Cash Incentive Compensation
For the fiscal year ended December 31, 2024, each of our NEOs was eligible to earn an annual bonus based on the Company's achievement of certain non-formulaic performance objectives, as determined by our board of directors. The target annual bonus for each of our named executive officers for the fiscal year ended December 31, 2024 was equal to the percentage of the executive’s respective annual base salary specified below:
| Name | Target Bonus Percentage from January 1, 2024 through September 15, 2024 | Target Bonus Percentage from September 16, 2024 through December 31, 2024* | ||||||||||||
Claire Mazumdar, Ph.D., M.B.A. | 45 | % | 55 | % | ||||||||||
Ryan Cohlhepp, Pharm.D. | 45 | % | 50 | % | ||||||||||
Ivan Hyep, M.B.A. | 40 | % | 40 | % | ||||||||||
* Target annual bonuses were increased for Drs. Mazumdar and Cohlhepp in connection with our IPO.
Following review and determination of our corporate performance for 2024, the board of directors determined to pay an annual cash bonus to each of our named executive officers for the fiscal year ended December 31, 2024 in the amount as set forth in the “Bonus” column of the “2024 Summary Compensation Table” above.
In September 26, 2021, we entered into a retention bonus letter agreement with Mr. Hyep, or the Hyep Retention Letter, that provides for a retention bonus in the aggregate amount of $500,000, payable in four equal installments on each of June 1, 2022, 2023, 2024, and 2025, subject to Mr. Hyep’s continued service with us through the applicable payment date. On that date, Mr. Hyep also executed a full recourse promissory note pursuant to which we loaned to Mr. Hyep $273,600, plus interest accruing at a rate of 0.86% per annum (the “Hyep Promissory Note”). As part of the Hyep Promissory Note, Mr. Hyep pledged 66,676 shares of restricted Common Stock as collateral under the terms of a security agreement. The Hyep Promissory Note required Mr. Hyep to annually pay $68,400 by December 31st. For more information, please see the Certain Relationships and Related Party Transactions – Agreements with our Executive Officers - Ivan Hyep Promissory Note section below. In connection with our IPO and to satisfy the full repayment of the Hyep Promissory Note prior to the completion of our IPO, the retention bonus letter agreement was amended in June 2024 so that the installment to be paid on June 1, 2025 would be paid on June 14, 2024; provided, that in the event that Mr. Hyep’s employment terminates prior to June 1, 2025 for any reason other than a termination by the Company without “cause” or a termination by Mr. Hyep for “good reason” (as such terms are defined in Mr. Hyep’s Amended Employment Agreement (as defined below)), Mr. Hyep would be obligated to repay to the Company the final $125,000 installment of the retention bonus. Following the acceleration of the installment, the Hyep Promissory Note was repaid in full in June 2024. The $250,000 retention bonus earned by Mr. Hyep during the fiscal year ended December 31, 2024 is reported under the “Bonus” column in the “2024 Summary Compensation Table” above.
In addition, during the fiscal year ended December 31, 2024, Mr. Hyep received a referral bonus in an amount equal to $5,000, as reported under the “Bonus” column in the “2024 Summary Compensation Table” above. Under the Company’s referral bonus program, employees are eligible to receive a referral bonus in the amount of $5,000
33
for each new hire referred to the Company, which amount is payable on the six-month anniversary of the referred employee’s start date with the Company.
Furthermore, Dr. Mazumdar and Dr. Cohlhepp each earned $10,000 in milestone bonuses in connection with the Company’s achievement of certain clinical development goals, as reported under the “Non-Equity Incentive Plan Compensation” column in the “2024 Summary Compensation Table” above.
Equity-Based Compensation
We believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our stockholders. In addition, we believe that equity grants promote executive retention because they incentivize our executive officers to remain in our employment during the vesting period. Accordingly, our board of directors or our compensation committee periodically reviews the equity incentive compensation of our named executive officers and may grant equity incentive awards to them from time to time. In furtherance of these goals, in 2024 each of our named executive officers was granted stock option awards. For additional information regarding outstanding equity awards held by our named executive officers as of December 31, 2024, see the “Outstanding Equity Awards at 2024 Fiscal Year End” table below.
In August 2024, our board of directors approved option grants in connection with our IPO to certain employees of the Company, including our named executive officers, with Dr. Mazumdar, Dr. Cohlhepp, and Mr. Hyep being granted options to purchase 1,141,342, 513,874 and 378,644 shares of our common stock, respectively. The options were granted under our 2019 Plan and have an exercise price per share equal to $9.24. The options will vest and become exercisable in sixteen (16) equal quarterly installments following their applicable vesting start date, in each case subject to the continued service relationship of the applicable named executive officer with the Company through each such vesting date.
401(k) Plan
We currently maintain a tax-qualified 401(k) retirement savings plan for our employees, including our named executive officers, who satisfy certain eligibility requirements. Our named executive officers are eligible to participate in the 401(k) plan on the same terms as other full-time employees. Our 401(k) plan is intended to qualify for favorable tax treatment under Section 401(a) of the Code and contains a cash or deferred feature that is intended to meet the requirements of Section 401(k) of the Code. Pursuant to our 401(k) plan we match 50% of each participating eligible employee's annual contributions to the plan, up to 6% of such employee's compensation for such year. Our 401(k) plan also provides for a profit-sharing component and we made certain profit-sharing contributions to the plan in 2024. We believe that providing a vehicle for tax-deferred retirement savings though our 401(k) plan adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our named executive officers, in accordance with our compensation policies. Other than the 401(k) plan, we do not provide any qualified or non-qualified retirement or deferred compensation benefits to our employees, including our named executive officers.
Other Benefits and Perquisites
Perquisites and other personal benefits are not a significant component of our executive compensation program. Accordingly, we do not provide perquisites or personal benefits to our named executive officers.
Outstanding Equity Awards at 2024 Fiscal Year End
The following table lists all outstanding equity awards held by our named executive officers as of December 31, 2024.
34
| Name | Grant Date | Vesting Commencement Date | Option Awards(1) | Stock Awards(1) | |||||||||||||||||||||||||
| Number of Securities Underlying Unexercised Options (#) Exercisable | Number of Securities Underlying Unexercised Options (#) Unexercisable | Option Exercise Price ($) | Option Expiration Date | Number of Shares or Units of Stock That Have Not Vested (#) | Market Value of Shares or Units of Stock That Have Not Vested ($)(2) | ||||||||||||||||||||||||
| Claire Mazumdar, Ph.D., M.B.A. | 11/19/2021 | 11/8/2021 | 66,673(3) | 24,308(3) | 4.10 | 11/19/2031 | |||||||||||||||||||||||
| 11/19/2021 | 11/8/2021 | 6,252(3) | 2,082(3) | 4.10 | 11/19/2031 | ||||||||||||||||||||||||
| 10/4/2022 | 10/4/2022 | 32,456(3) | 32,454(3) | 4.44 | 10/4/2032 | ||||||||||||||||||||||||
| 4/5/2023 | 4/5/2023 | 23,056(3) | 114,944(3) | 3.79 | 4/5/2033 | ||||||||||||||||||||||||
| 8/8/2023 | 8/8/2023 | 69,882(3) | 256,225(3) | 3.79 | 8/8/2033 | ||||||||||||||||||||||||
| 12/14/2023 | 12/14/2023 | 148,756(3) | 446,256(3) | 5.45 | 12/14/2033 | ||||||||||||||||||||||||
| 8/13/2024 | 8/13/2024 | 71,334(3) | 1,070,008(3) | 9.24 | 8/13/2034 | ||||||||||||||||||||||||
| Ryan Cohlhepp, Pharm. D | 11/19/2021 | 11/8/2021 | 1,043(3) | 2,083(3) | 4.10 | 11/19/2031 | |||||||||||||||||||||||
| 11/19/2021 | 11/8/2021 | 5,904(3) | 11,806(3) | 4.10 | 11/19/2031 | ||||||||||||||||||||||||
| 10/4/2022 | 10/4/2022 | 32,458(3) | 32,451(3) | 4.44 | 10/4/2032 | ||||||||||||||||||||||||
| 4/5/2023 | 4/5/2023 | 14,876(3) | 74,376(3) | 3.79 | 4/5/2033 | ||||||||||||||||||||||||
| 8/8/2023 | 8/8/2023 | 30,360(3) | 166,974(3) | 3.79 | 8/8/2033 | ||||||||||||||||||||||||
| 12/14/2023 | 12/14/2023 | 94,664(3) | 283,980(3) | 5.45 | 12/14/2033 | ||||||||||||||||||||||||
| 8/13/2024 | 8/13/2024 | 32,118(3) | 481,756(3) | 9.24 | 8/13/2034 | ||||||||||||||||||||||||
| Ivan Hyep, M.B.A. | 2/22/2021 | 3/15/2021 | 4,167(4) | 72,589 | |||||||||||||||||||||||||
| 11/19/2021 | 11/8/2021 | 4,168(3) | 8,333(3) | 4.10 | 11/19/2031 | ||||||||||||||||||||||||
| 10/4/2022 | 10/4/2022 | 32,456(3) | 32,453(3) | 4.44 | 10/4/2032 | ||||||||||||||||||||||||
| 4/5/2023 | 4/5/2023 | 11,225(3) | 56,119(3) | 3.79 | 4/5/2033 | ||||||||||||||||||||||||
| 8/8/2023 | 8/8/2023 | 23,598(3) | 129,786(3) | 3.79 | 8/8/2033 | ||||||||||||||||||||||||
| 12/14/2023 | 12/14/2023 | 70,320(3) | 210,958(3) | 5.45 | 12/14/2033 | ||||||||||||||||||||||||
| 8/13/2024 | 8/13/2024 | 23,666(3) | 354,978(3) | 9.24 | 8/13/2034 | ||||||||||||||||||||||||
| (1) | Each award granted prior to September 2024 was granted under the Bicara Therapeutics Inc. 2019 Stock Option and Grant Plan, as amended from time to time, or the 2019 Plan, and each award granted during or after September 2024 was granted under the Bicara Therapeutics Inc. 2024 Stock Option and Grant Plan, or the 2024 Plan. | ||||
| (2) | Represents the fair market value of the shares that were unvested as of December 31, 2024, based on the closing market price of our common stock on December 31, 2024, the last trading day of fiscal year 2024, of $17.42. | ||||
| (3) | The shares underlying the stock option award vest in 16 equal quarterly installments over a four-year period, commencing on the vesting commencement date, subject to the applicable named executive officer’s continued employment through the applicable vesting date. The award is also subject to certain accelerated vesting rights as set forth in the applicable named executive officer’s Second Amended Employment Agreement, as described below. | ||||
| (4) | The shares vest as follows: 25% of such shares vested on the first anniversary of the vesting commencement date, and the remaining 75% of the shares vest in 12 equal quarterly installments over the following three years, subject to the applicable named executive officer’s continued employment through the applicable vesting date. The award is also subject to certain accelerated vesting rights as set forth in the applicable NEO’s Second Amended Employment Agreement, as described below. | ||||
Employment Arrangements for Named Executive Officers from January 1, 2024 through February 29, 2024
Claire Mazumdar, Ph.D., M.B.A.
Effective as of January 6, 2020, the Company entered into an employment agreement with Dr. Mazumdar, as amended by the First Amendment to Employment Agreement effective as of November 3, 2023, for the position of Chief Executive Officer, or the Prior Mazumdar Employment Agreement. The Prior Mazumdar Employment Agreement provided for Dr. Mazumdar’s at-will employment, and an initial annual base salary and initial target
35
annual incentive compensation amount, each of which has subsequently been increased. The Prior Mazumdar Employment Agreement also provided for an initial grant of a number of shares of restricted stock. Under the terms of the Prior Mazumdar Employment Agreement, Dr. Mazumdar was eligible to participate in the employee benefit plans generally available to employees, subject to the terms of those plans.
In addition, the Prior Mazumdar Employment Agreement provided that in the event that Dr. Mazumdar’s employment was terminated by the Company without “cause” or she resigned for “good reason” (as each term was defined in the Prior Mazumdar Employment Agreement), subject to Dr. Mazumdar’s execution and the effectiveness of a separation agreement, including a general release of claims in the Company’s favor, she would have been entitled to receive (i) base salary continuation for 12 months following termination, (ii) subject to the Company’s attainment of the applicable performance goals for the applicable fiscal year, a pro-rated portion of her target cash incentive compensation for the year of termination, (iii) subject to Dr. Mazumdar’s copayment of premium amounts at the applicable active employees’ rate and proper election to continue COBRA health coverage, payment of the portion of the premium equal to the amount that the Company would have paid to provide health insurance to Dr. Mazumdar had she remained employed with the Company until the earliest of (A) 12 months following termination, (B) Dr. Mazumdar’s eligibility for group medical plan benefits under any other employer’s group medical plan, or (C) the end of Dr. Mazumdar’s COBRA health continuation period, and (iv) if such termination had occurred within 12 months immediately following a “sale event” (as such term was defined in the Prior Mazumdar Employment Agreement), accelerated vesting of all time-based stock options held by Dr. Mazumdar.
Pursuant to the Prior Mazumdar Employment Agreement, in the event that Dr. Mazumdar’s employment terminated for any reason, she would have been entitled to receive any earned but unpaid annual bonus for the year prior to the year of termination. Pursuant to the Prior Mazumdar Employment Agreement, in the event that Dr. Mazumdar’s employment terminated due to her death or disability, she would have been entitled to receive a pro-rated portion of her target cash incentive compensation for the year of termination, subject to the Company’s attainment of the applicable performance goals for such year.
Dr. Mazumdar also entered into a standard form agreement with respect to confidential information, intellectual property assignment and non-competition and non-solicitation restrictions.
Ryan Cohlhepp, Pharm.D.
Effective as of October 19, 2020, the Company entered into an employment agreement with Dr. Cohlhepp, as amended by the First Amendment to Employment Agreement effective as of November 3, 2023, for the position of President and Chief Operating Officer, or the Prior Cohlhepp Employment Agreement. The Prior Cohlhepp Employment Agreement provided for Dr. Cohlhepp’s at-will employment, and an initial annual base salary and initial target annual incentive compensation amount, each of which has subsequently been increased. The Prior Cohlhepp Employment Agreement also provided for an initial grant of a number of shares of restricted stock. Under the Prior Cohlhepp Employment Agreement, Dr. Cohlhepp was eligible to participate in the employee benefit plans generally available to employees, subject to the terms of those plans.
In addition, the Prior Cohlhepp Employment Agreement provided that in the event that Dr. Cohlhepp’s employment was terminated by the Company without “cause” or he resigned for “good reason” (as each term was defined in the Prior Cohlhepp Employment Agreement), subject to Dr. Cohlhepp’s execution and the effectiveness of a separation agreement, including a general release of claims in the Company’s favor, he would have been entitled to receive (i) base salary continuation for 12 months following termination, (ii) subject to the Company’s attainment of the applicable performance goals for the applicable fiscal year, a pro-rated portion of his target cash incentive compensation for the year of termination, (iii) subject to Dr. Cohlhepp’s copayment of premium amounts at the applicable active employees’ rate and proper election to continue COBRA health coverage, payment of the portion of the premium equal to the amount that the Company would have paid to provide health insurance to Dr. Cohlhepp had he remained employed with the Company until the earliest of (A) 12 months following termination, (B) Dr. Cohlhepp’s eligibility for group medical plan benefits under any other employer’s group medical plan, or (C) the end of Dr. Cohlhepp’s COBRA health continuation period, and (iv) if such termination had
36
occurred within 12 months immediately following a “sale event” (as such term was defined in the Prior Cohlhepp Employment Agreement), accelerated vesting of all time-based stock options held by Dr. Cohlhepp.
Pursuant to the Prior Cohlhepp Employment Agreement, in the event that Dr. Cohlhepp’s employment terminated for any reason, he would have been entitled to receive any earned but unpaid annual bonus for the year prior to the year of termination. Pursuant to the Prior Cohlhepp Employment Arrangement, in the event that Dr. Cohlhepp’s employment terminated due to his death or disability, he would have been entitled to receive a pro-rated portion of his target cash incentive compensation for the year of termination, subject to the Company’s attainment of the applicable performance goals for such year.
Dr. Cohlhepp also entered into a standard form agreement with respect to confidential information, intellectual property assignment and non-competition and non-solicitation restrictions.
Ivan Hyep, M.B.A.
On February 8, 2021, the Company entered into an offer letter with Mr. Hyep, as amended by the First Amendment to Employment Agreement effective as of November 3, 2023 for the position of Chief Financial Officer, or the Prior Hyep Employment Arrangement. The Prior Hyep Employment Arrangement provided for Mr. Hyep’s at-will employment, and an initial annual base salary and initial target annual incentive compensation amount, each of which has subsequently been increased. The Prior Hyep Employment Arrangement also provided for an initial grant of a number of shares of restricted stock or a stock option award. Under the Prior Hyep Employment Arrangement, Mr. Hyep was eligible to participate in the employee benefit plans generally available to employees, subject to the terms of those plans.
In addition, the Prior Hyep Employment Arrangement provided that in the event that Mr. Hyep’s employment was terminated by the Company without “cause” (as such term was defined in the Prior Hyep Employment Arrangement), subject to Mr. Hyep’s signing and not revoking a separation agreement and release of claims in the Company’s favor, he would have been entitled to receive (i) base salary continuation for 12 months following termination, and (ii) subject to Mr. Hyep’s copayment of premium amounts at the applicable active employees’ rate and proper election to continue COBRA health coverage, payment of the portion of the premium equal to the amount that the Company would have paid to provide health insurance to Mr. Hyep had he remained employed with the Company until the earliest of (A) 12 months following termination, (B) Mr. Hyep’s eligibility for group medical plan benefits under any other employer’s group medical plan, or (C) the end of Mr. Hyep’s COBRA health continuation period.
Mr. Hyep also entered into a standard form agreement with respect to confidential information, intellectual property assignment and non-competition and non-solicitation restrictions.
Employment Arrangements for Named Executive Officers from March 1, 2024 through September 16, 2024
Amended Employment Agreements
Effective as of March 1, 2024, the Company entered into amended and restated employment agreements with Dr. Mazumdar, Dr. Cohlhepp, and Mr. Hyep (collectively, the “Amended Employment Agreements”), that supersede in all respects all prior employment agreements, offer letters and severance agreements between Dr. Mazumdar, Dr. Cohlhepp, Mr. Hyep, respectively, and the Company, including the Prior Mazumdar Employment Agreement, the Prior Cohlhepp Employment Agreement, and the Prior Hyep Employment Arrangement, each as described above.
Under the Amended Employment Agreements, each of the NEOs continued to serve in their respective roles on an at-will basis. The Amended Employment Agreements provided for each NEO’s base salary, which was subject to periodic review by our board of directors or the compensation committee, and a target annual cash incentive opportunity, with the actual amount of any annual cash bonus determined by our board of directors or the compensation committee, subject to the terms of any applicable incentive compensation plan that may be in effect
37
from time to time. The NEOs were also eligible to participate in the Company’s U.S. employee benefit plans available to employees, subject to the terms of those plans.
Pursuant to the Amended Employment Agreements, in the event that an NEO’s employment was terminated by the Company without “cause” or the NEO resigns for “good reason”, in either case outside of the one-year period following a “change in control” (as each such term is defined in the Amended Employment Agreements), subject to the applicable NEO signing a separation agreement and release of claims in the Company’s favor and such separation agreement and release becoming fully effective no more than 60 days after the termination date, such NEO was entitled to receive (i) base salary continuation for 12 months following termination, (ii) subject to the Company’s attainment of the applicable pre-established performance goals for the year of termination, a pro-rated portion of such NEO’s target cash incentive compensation for the year of termination, or Pro-Rata Bonus, and (iii) subject to the applicable NEO’s copayment of premium amounts at the applicable active employees’ rate and proper election to continue COBRA health coverage, payment of the portion of the premium equal to the amount that we would have paid to provide health insurance to such NEO had he or she remained employed with the Company until the earliest of (A) 12 months following termination, (B) the applicable NEO’s eligibility for group medical plan benefits under any other employer’s group medical plan, or (C) the end of the applicable NEO’s COBRA health continuation period.
Pursuant to the Amended Employment Agreements, in lieu of the payments and benefits described in the preceding sentence, in the event that the NEO’s employment was terminated by the Company without cause or the NEO resigned for good reason, in either case within one year following a change in control, subject to the applicable NEO signing a separation agreement and release of claims in the Company’s favor and such separation agreement and release becoming fully effective no more than 60 days after the termination date, such NEO was entitled to receive (i) 12 months of such NEO’s then-current annual base salary (or such NEO’s annual base salary in effect immediately prior to the change in control, if higher), payable in a lump sum, (ii) a Pro-Rata Bonus, (iii) subject the applicable NEO’s copayment of premium amounts at the applicable active employees’ rate and proper election to continue COBRA health coverage, payment of the portion of the premium equal to the amount that the Company would have paid to provide health insurance to such NEO had he or she remained employed with the Company until the earliest of (A) 12 months following termination, (B) the applicable NEO’s eligibility for group medical plan benefits under any other employer’s group medical plan, or (C) the end of the applicable NEO’s COBRA health continuation period, and (iv) full accelerated vesting of 100% of all stock options and other stock-based awards subject solely to time-based vesting held by such NEO.
Pursuant to the Amended Employment Agreements, in the event that an NEO’s employment was terminated for any reason, such NEO was entitled to receive any earned but unpaid annual bonus for the year prior to the year of termination. In the event that an NEO’s employment is terminated due to the NEO’s death or disability, such NEO would also have been entitled to receive a Pro-Rata Bonus.
Pursuant to the Amended Employment Agreements, if the payments and benefits payable to the applicable NEO in connection with a change in control would be subject to the excise tax on golden parachutes imposed under Section 4999 of the Code, then those payments or benefits will be reduced if such reduction would result in a higher net after-tax benefit to the applicable NEO than if he or she had been paid the full amount of such payments and benefits, with such amount subject to the excise tax.
The standard form agreement with respect to confidential information, intellectual property assignment and non-competition and non-solicitation restrictions that the NEOs entered into before our IPO remain in full force and effect.
38
Current Employment Arrangements for Named Executive Officers since September 16, 2024
Second Amended Employment Agreements
Effective as of the closing of our IPO on September 16, 2024, the Company entered into second amended and restated employment agreements with Dr. Mazumdar, Dr. Cohlhepp, and Mr. Hyep (collectively, the “Second Amended Employment Agreements”), that supersede in all respects all prior employment agreements, offer letters and severance agreements between Dr. Mazumdar, Dr. Cohlhepp, Mr. Hyep, respectively, and the Company, including the Amended Employment Agreements, described above.
Under the Second Amended Employment Agreements, each of the NEOs continues to serve in their respective roles on an at-will basis. The Second Amended Employment Agreements provide for each NEO’s base salary, which is subject to periodic review by our board of directors or the compensation committee, and a target annual cash incentive opportunity, with the actual amount of any annual cash bonus determined by our board of directors or the compensation committee, subject to the terms of any applicable incentive compensation plan that may be in effect from time to time. Dr. Mazumdar, Dr. Cohlhepp and Mr. Hyep’s initial Base Salary (as defined in Second Amended Employment Agreements) will be $560,000, $560,000 and $470,000, respectively and their initial Target Bonus (as defined in Second Amended Employment Agreements) will be 55%, 50% and 40%, respectively. The NEOs are also eligible to participate in the Company’s U.S. employee benefit plans available to employees, subject to the terms of those plans.
Pursuant to the Second Amended Employment Agreements, in the event that an NEO’s employment terminates for any reason, the NEO shall be entitled to (i) any Base Salary earned through the Date of Termination (as defined in the Second Amended Employment Agreements); (ii) unpaid expense reimbursements (iii) if the Date of Termination occurs after the completion of a calendar year but prior to the payment of annual bonuses for such year, the Company will pay the NEO the bonus amount that the Executive otherwise would have earned if the NEO remained employed on the date of payment, as determined in the sole discretion of the board or compensation committee; and (iv) any vested benefits the NEO may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans. In addition, if the NEO’s employment with the Company is terminated due to the NEO’s death or disability, then subject to the Company’s attainment of the applicable preestablished performance goals for the calendar year in which the Date of Termination occurs, if any, a pro rata portion of the Target Bonus which would have been earned by the NEO with respect to such calendar year, based upon the number of days the NEO was employed with the Company during such calendar year.
Pursuant to the Second Amended Employment Agreements, in the event that an NEO’s employment is terminated by the Company without “Cause” or the NEO resigns for “Good Reason,” in either case outside of a “Change in Control Period” (as each term is defined in the Second Amended Employment Agreements), subject to the applicable NEO signing a separation agreement and release of claims in the Company’s favor and such separation agreement and release becoming fully effective no more than 60 days after the termination date (a “Release”), such NEO will be entitled to receive (i) Base Salary continuation for 12 months following termination, (ii) subject to the applicable NEO’s copayment of premium amounts at the applicable active employees’ rate and proper election to continue COBRA health coverage, payment of the portion of the premium equal to the amount that we would have paid to provide health insurance to such NEO had he or she remained employed with the Company until the earliest of (A) 12 months following termination, (B) the applicable NEO’s eligibility for group medical plan benefits under any other employer’s group medical plan, or (C) at the end of the applicable NEO’s COBRA health continuation period.
Pursuant to the Second Amended Employment Agreements, in lieu of the payments and benefits described in the preceding paragraph, in the event that the NEO’s employment is terminated by the Company without Cause or the NEO resigns for Good Reason, in either case within a “Change in Control Period” and the “Change in Control” is not a “Specified Transaction” (as those terms are defined in the Second Amended Employment Agreements), subject to the applicable NEO signing and not revoking a Release, the NEO will be entitled to receive (i) the NEO’s then-current Base Salary (or such NEO’s annual Base Salary in effect immediately prior to the Change in Control, if
39
higher), payable in a lump sum, (ii) subject to applicable NEO’s copayment of premium amounts at the applicable active employees’ rate and proper election to continue COBRA health coverage, payment of the portion of the premium equal to the amount that the Company would have paid to provide health insurance to such NEO had he or she remained employed with the Company until the earliest of (A) 12 months following termination, (B) the applicable NEO’s eligibility for group medical plan benefits under any other employer’s group medical plan, or (C) the end of the applicable NEO’s COBRA health continuation period, and (iii) full accelerated vesting of 100% of all stock options and other stock-based awards subject solely to time-based vesting held by such NEO.
Pursuant to the Second Amended Employment Agreements, in the event that the NEO’s employment is terminated by the Company without Cause or the NEO resigns for Good Reason, in either case within a Change in Control Period and the Change in Control is a Specified Transaction, subject to the applicable NEO entering into and not revoking a Release, and lieu of the payments and benefits in the preceding paragraphs, (1) Dr. Mazumdar and Dr. Cohlhepp shall receive (i) a lump sum cash in the amount of 1.5 x the sum of their respective Base Salary and Target Bonus, (ii) subject to applicable NEO’s copayment of premium amounts at the applicable active employees’ rate and proper election to continue COBRA health coverage, payment of the portion of the premium equal to the amount that the Company would have paid to provide health insurance to such NEO had they remained employed with the Company until the earliest of (A) 18 months following the Date of Termination, (B) the applicable NEO’s eligibility for group medical plan benefits under any other employer’s group medical plan, or (C) the end of the applicable NEO’s COBRA health continuation period, and (iii) full accelerated vesting of 100% of all stock options and other stock-based awards subject solely to time-based vesting held by such NEO, (2) Mr. Hyep shall receive (i) a lump sum cash in the amount of his Base Salary and Target Bonus; and (ii) subject to his copayment of premium amounts at the applicable active employees’ rate and proper election to continue COBRA health coverage, payment of the portion of the premium equal to the amount that the Company would have paid to provide health insurance had he remained employed with the Company until the earliest of (A) 12 months following the Date of Termination, (B) his eligibility for group medical plan benefits under any other employer’s group medical plan, or (C) the end of his COBRA health continuation period, and (iii) full accelerated vesting of 100% of all stock options and other stock-based awards subject solely to time-based vesting held by Mr. Hyep.
Pursuant to the Second Amended Employment Agreements, the Change in Control Period shall be the one-year period following the Change in Control, provided that if the Change in Control is a Specified Transaction, the Change in Control Period shall also include the 3 months before the Change in Control.
Pursuant to the Amended Employment Agreements, if the payments and benefits payable to the applicable NEO in connection with a Change in Control would be subject to the excise tax on golden parachutes imposed under Section 4999 of the Code, then those payments or benefits will be reduced if such reduction would result in a higher net after-tax benefit to the applicable NEO than if he or she had been paid the full amount of such payments and benefits, with such amount subject to the excise tax.
The standard form agreement with respect to confidential information, intellectual property assignment and non-competition and non-solicitation restrictions that the NEOs entered into before our IPO remains in full force and effect.
Compensation Risk Assessment
We believe that although a portion of the compensation provided to our executive officers and other employees is performance-based, our executive compensation program does not encourage excessive or unnecessary risk taking. Our compensation programs are designed to encourage our executive officers and other employees to remain focused on both short-term and long-term strategic goals, in particular in connection with our pay-for-performance compensation philosophy. As a result, we do not believe that our compensation programs are reasonably likely to have a material adverse effect on us.
40
Equity Compensation Plan Information
The following table provides information as of December 31, 2024 with respect to the shares of our common stock that may be issued under our existing equity compensation plans.
| Equity Compensation Plan Information | ||||||||||||||
| Plan Category | Number of securities to be issued upon exercise of outstanding options, warrants and rights | Weighted average exercise price of outstanding options, warrants and rights(1) | Number of securities remaining available for future issuance under equity compensation plans (excluding securities in first column) | |||||||||||
Equity compensation plans approved by security holders (2) | 8,038,679(3) | $ | 7.02 | 2,209,643(4) | ||||||||||
| Equity compensation plans not approved by security holders | — | — | — | |||||||||||
| Total | $ | 8,038,679 | $ | 7.02 | $ | 2,209,643 | ||||||||
| (1) | The weighted average exercise price is calculated based solely on outstanding stock options. | ||||
| (2) | Includes the following plans: our 2019 Plan, our 2024 Plan and our 2024 Employee Stock Purchase Plan (the “2024 ESPP”). | ||||
| (3) | Includes 8,038,679 shares subject to options that were outstanding as of December 31, 2024 that were issued under the 2019 Plan and the 2024 Plan. | ||||
| (4) | As of December 31, 2024, a total of 2,209,643 shares of our common stock have been reserved for issuance pursuant to the 2024 Plan. The 2024 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2025, by 5% of the Outstanding Shares (as defined in the 2024 Plan and which includes the number of shares issued and outstanding as well as the number of shares issuable pursuant to the exercise of any outstanding, pre-funded warrants to acquire stock for a nominal exercise price) on the immediately preceding December 31 or such lesser number of shares as determined by the Administrator (as such term is defined in the 2024 Plan). This number is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. The shares of common stock underlying any awards that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without the issuance of stock, expire or are otherwise terminated, other than by exercise, under the 2024 Plan and the 2019 Plan will be added back to the shares of common stock available for issuance under the 2024 Plan. We no longer make grants under the 2019 Plan. As of December 31, 2024, a total of 507,383 shares of our common stock have been reserved for issuance pursuant to the 2024 ESPP. The 2024 ESPP provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2025, by the least of 1,014,766 shares of our common stock, 1% of the Outstanding Shares (as defined in the 2024 ESPP and which includes the number of shares issued and outstanding as well as the number of shares issuable pursuant to the exercise of any outstanding, pre-funded warrants to acquire stock for a nominal exercise price) on the immediately preceding December 31 or such lesser number of shares as determined by the Administrator (as such term is defined in the 2024 ESPP). This number is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. Shares of our common stock available for issuance as of December 31, 2024 pursuant to the 2024 Plan exclude the 2,722,001 shares that were added to the plans as a result of the automatic annual increase on January 1, 2025. The Administrator elected to waive the automatic January 1, 2025 annual increase for the 2024 ESPP. | ||||
41
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Certain Relationships and Transactions
Other than the compensation agreements and other arrangements described under “Executive Compensation” and “Director Compensation” in this proxy statement and the transactions described below, since January 1, 2023, there has not been and there is not currently proposed, any transaction or series of similar transactions to which we were, or will be, a party in which the amount involved exceeded, or will exceed, $120,000 (or, if less, 1% of the average of our total assets amounts at December 31, 2023 and 2024) and in which any director, executive officer, holder of five percent or more of any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had, or will have, a direct or indirect material interest.
Series B Preferred Stock Financing
Initial Closing and Additional Closing
In March 2023, in connection with the initial and additional closings of our Series B preferred stock financing, we sold an aggregate of 37,073,162 shares of our Series B preferred stock at a purchase price of $1.025 per share for an aggregate purchase price of approximately $38.0 million. Each share of our Series B preferred stock automatically converted into approximately 0.1082 shares of our common stock immediately prior to the completion of our initial public offering. The following table summarizes purchases of our Series B preferred stock by related persons:
| Participant | Affiliated Director(s) or Officer(s) | Shares of Series B Preferred Stock | Total Purchase Price | |||||||||||||||||
RA Capital Healthcare Fund, L.P.(1) | Jake Simson, Ph.D. | 6,463,442 | $ | 6,625,028.05 | ||||||||||||||||
RA Capital Nexus Fund III, L.P.(1) | Jake Simson, Ph.D. | 4,308,961 | $ | 4,416,685.03 | ||||||||||||||||
Red Tree Venture Fund, L.P.(2) | Heath Lukatch, Ph.D | 5,994,183 | $ | 6,144,037.58 | ||||||||||||||||
Omega Fund VII, L.P.(3) | — | 4,795,347 | $ | 4,915,230.68 | ||||||||||||||||
Invus Public Equities, L.P.(4) | — | 2,740,198 | $ | 2,808,702.95 | ||||||||||||||||
| (1) | Such entity is affiliated with RA Capital Management, L.P., or collectively with its affiliates RA Capital, which holds five percent or more of our capital stock. Dr. Simson is a partner at RA Capital and a member of our board of directors. | ||||
| (2) | Such entity is affiliated with Red Tree Venture Fund, L.P., or Red Tree, which holds five percent or more of our capital stock. | ||||
| (3) | Such entity was a holder of five percent or more of our capital stock at the time of the transaction. | ||||
| (4) | Such entity holds five percent or more of our capital stock. | ||||
Milestone Tranche 1 Closing
In September 2023, in connection with the milestone tranche 1 closing of our Series B preferred stock financing, we sold an aggregate of 39,024,386 shares of our Series B preferred stock at a purchase price of $1.025 per share for an aggregate purchase price of approximately $40.0 million. Each share of our Series B preferred stock automatically converted into approximately 0.1082 shares of our common stock immediately prior to the completion of our initial public offering. The following table summarizes purchases of our Series B preferred stock by related persons:
42
| Participant | Affiliated Director(s) or Officer(s) | Shares of Series B Preferred Stock | Total Purchase Price | |||||||||||||||||
RA Capital Healthcare Fund, L.P.(1) | Jake Simson, Ph.D. | 6,803,624 | $ | 6,973,714.60 | ||||||||||||||||
RA Capital Nexus Fund III, L.P.(1) | Jake Simson, Ph.D. | 4,535,749 | $ | 4,649,142.73 | ||||||||||||||||
Red Tree Venture Fund, L.P.(2) | Heath Lukatch, Ph.D | 6,309,667 | $ | 6,467,408.68 | ||||||||||||||||
Omega Fund VII, L.P.(3) | — | 5,047,733 | $ | 5,173,926.33 | ||||||||||||||||
Invus Public Equities, L.P.(4) | — | 2,884,419 | $ | 2,956,529.48 | ||||||||||||||||
| (1) | Such entity is affiliated with RA Capital Management, L.P., or collectively with its affiliates RA Capital, which holds five percent or more of our capital stock. Dr. Simson is a partner at RA Capital and a member of our board of directors. | ||||
| (2) | Such entity is affiliated with Red Tree Venture Fund, L.P., or Red Tree, which holds five percent or more of our capital stock. | ||||
| (3) | Such entity was a holder of five percent or more of our capital stock at the time of the transaction. | ||||
| (4) | Such entity holds five percent or more of our capital stock. | ||||
Milestone Tranche 2 Closing
In November 2023, in connection with the milestone tranche 2 closing of our Series B preferred stock financing, we sold an aggregate of 29,497,553 shares of our Series B preferred stock at a purchase price of $1.025 per share for an aggregate purchase price of approximately $30.2 million. Each share of our Series B preferred stock automatically converted into approximately 0.1082 shares of our common stock immediately prior to the completion of our initial public offering. The following table summarizes purchases of our Series B preferred stock by related persons:
| Participant | Affiliated Director(s) or Officer(s) | Shares of Series B Preferred Stock | Total Purchase Price | |||||||||||||||||
RA Capital Healthcare Fund, L.P.(1) | Jake Simson, Ph.D. | 5,142,689 | $ | 5,271,256.23 | ||||||||||||||||
RA Capital Nexus Fund III, L.P.(1) | Jake Simson, Ph.D. | 3,428,459 | $ | 3,514,170.48 | ||||||||||||||||
Red Tree Venture Fund, L.P.(2) | Heath Lukatch, Ph.D | 4,769,319 | $ | 4,888,551.98 | ||||||||||||||||
Omega Fund VII, L.P.(3) | — | 3,815,455 | $ | 3,910,841.38 | ||||||||||||||||
Invus Public Equities, L.P.(4) | — | 2,180,260 | $ | 2,234,766.50 | ||||||||||||||||
| (1) | Such entity is affiliated with RA Capital Management, which holds five percent or more of our capital stock. Dr. Simson is a partner at RA Capital and a member of our board of directors. | ||||
| (2) | Such entity is affiliated with Red Tree, which holds five percent or more of our capital stock. | ||||
| (3) | Such entity was a holder of five percent or more of our capital stock at the time of the transaction. | ||||
| (4) | Such entity which holds five percent or more of our capital stock. | ||||
Series C Preferred Stock Financing
In December 2023, we sold an aggregate of 119,599,872 shares of our Series C preferred stock at a purchase price of $1.3796 per share for an aggregate purchase price of approximately $165.0 million. Each share of our Series C preferred stock automatically converted into approximately 0.1082 of our common stock immediately prior to the completion of our initial public offering. The following table summarizes purchases of our Series C preferred stock by related persons:
43
| Participant | Affiliated Director(s) or Officer(s) | Shares of Series C Preferred Stock | Total Purchase Price | |||||||||||||||||
TPG LSI Rise Butterfly, LP(1) | Carolyn Ng, Ph.D. | 18,121,194 | $ | 24,999,999.25 | ||||||||||||||||
RA Capital Healthcare Fund, L.P.(2) | Jake Simson, Ph.D. | 5,835,024 | $ | 8,049,999.12 | ||||||||||||||||
RA Capital Nexus Fund III, L.P.(2) | Jake Simson, Ph.D. | 10,836,474 | $ | 14,949,999.54 | ||||||||||||||||
Omega Fund VII, L.P.(3) | — | 5,436,358 | $ | 7,499,999.50 | ||||||||||||||||
Red Tree Venture Fund, L.P.(4) | Heath Lukatch, Ph.D. | 3,624,238 | $ | 4,999,998.75 | ||||||||||||||||
Invus Public Equities, L.P.(5) | — | 3,624,238 | $ | 4,999,998.75 | ||||||||||||||||
| (1) | Such entity is affiliated with TPG, which holds five percent or more of our capital stock. Dr. Ng is a partner and managing director at TPG and a member of our board of directors. | ||||
| (2) | Such entity is affiliated with RA Capital, which holds five percent or more of our capital stock. Dr. Simson is a partner at RA Capital and a member of our board of directors. | ||||
| (3) | Such entity was a holder of five percent or more of our capital stock at the time of the transaction. | ||||
| (4) | Such entity is affiliated with Red Tree, which holds five percent or more of our capital stock. Dr. Lukatch is the managing partner at Red Tree and a member of our board of directors. | ||||
| (5) | Such entity holds five percent or more of our capital stock. | ||||
Participation in our IPO
Our existing stockholders, including certain affiliates of our directors, purchased an aggregate of 2,0125,000 shares of our common stock in our initial public offering in September 2024, or IPO, at the initial public offering price at $18.00. The following table sets forth the number of shares of our common stock purchased by directors, executive officers and five percent stockholders and their affiliates and the aggregate purchase price paid for such shares.
| Stockholder | Shares of Common Stock | Total Purchase Price | ||||||||||||
Entities affiliated with TPG LSI Rise Butterfly, LP.(1) | 1,050,000 | $ | 18,900,000 | |||||||||||
Entities affiliated with RA Capital Healthcare Fund, L.P.(2) | 1,833,000 | $ | 32,994,000 | |||||||||||
Entities affiliated with BWP SPV LLC.(3) | 1,555,000 | $ | 27,990,000 | |||||||||||
Entities affiliated with Red Tree Venture Fund, L.P.(4) | 120,000 | $ | 2,160,000 | |||||||||||
Entities affiliated with Invus Public Equities, L.P.(5) | 825,000 | $ | 14,850,000 | |||||||||||
| (1) | Entities affiliated with TPG hold five percent or more of our capital stock. Dr. Ng is a partner and managing director at TPG and a member of our board of directors. | ||||
| (2) | Entities affiliated with RA Capital hold five percent or more of our capital stock. Dr. Simson is a partner at RA Capital and a member of our board of directors. | ||||
| (3) | Such entity holds five percent or more of our capital stock. | ||||
| (4) | Entities affiliated with Red Tree hold five percent or more of our capital stock. | ||||
| (5) | Such entity holds five percent or more of our capital stock. | ||||
Agreements with Our Executive Officers
Ivan Hyep Promissory Note
In September 2021, we entered into a full recourse promissory note, or the Hyep Promissory Note, with Ivan Hyep, our Chief Financial Officer, pursuant to which we loaned to Mr. Hyep $273,600, plus interest accruing at rate of 0.86% per annum (or if higher, the applicable federal rate as of the date of the Hyep Promissory Note), due by the earliest to occur of (i) December 31, 2025, (ii) the date of certain transfers by Mr. Hyep of the collateral pledged
44
under the Hyep Promissory Note, (iii) upon the day prior to the date a change in the Company’s or Mr. Hyep’s status would cause the loan to be deemed prohibited under applicable law, (iv) upon the date prior to the Company’s filing of a registration statement for an initial public offering or a change of control, (v) upon acceleration of the Hyep Promissory Note in accordance with its terms or (vi) the date three months following Mr. Hyep’s termination of employment with the Company. As part of the Hyep Promissory Note, Mr. Hyep pledged 66,676 shares of restricted Common Stock as collateral under the terms of a security agreement. Mr. Hyep has repaid $69,282 in principal and interest in July 2023. The Hyep Promissory Note was repaid in full in June 2024 with a final payment of $137,832.
Agreements with Our Stockholders
Entities affiliated with Biocon
Entities affiliated with Biocon Limited, or collectively Biocon, is a holder of greater than 5% of our securities and Ms. Mazumdar-Shaw is the Executive Chairperson of Biocon and a member of our board of directors. Below is a summary of the transactions between Biocon and us since January 1, 2023.
Syngene Agreements
In April 2020, we entered into an amended and restated master manufacturing services agreement, and further amended, or the Syngene Manufacturing Services Agreement, with Syngene International Limited, or Syngene, an affiliate of Biocon. Under the Syngene Manufacturing Services Agreement, Syngene provides contract development and manufacturing for drug products pursuant to statements of work. In July 2020, we entered into a master contract services agreement and further amended, or the Syngene Contract Services Agreement, with Syngene. Under the Syngene Contract Services Agreement, Syngene provides contract research and project management services for drug products pursuant to statements of work. In December 2024, the Company entered into an additional master contract services agreement with Syngene, or the Syngene Dedicated Services Agreement. Under the Dedicated Services Agreement, Syngene provides dedicated research laboratories and personnel. We have made payments to Syngene under the Syngene Manufacturing Services Agreement, Syngene Contract Services Agreement and Syngene Dedicated Center Agreement together totaling $7,738,383 in 2023 and $9,830,124 in 2024.
Biofusion Therapeutics Limited Services Agreement
In July 2021, the Company entered into a master services agreement with Biofusion Therapeutics Limited, or Biofusion, a wholly owned subsidiary of Biocon, or the Biofusion Services Agreement, pursuant to which Biofusion provided certain research and development services to the Company. Biofusion was acquired by Syngene on August 2, 2022, and, in connection with such acquisition, the Biofusion Services Agreement was terminated in August 2022. Upon the termination of the Biofusion Services Agreement, the Company, Biocon and Syngene determined the Company incurred expenses in connection with services provided under the Biofusion Services Agreement. All of such amounts were classified as accrued expenses of the Company and repaid in full in March 2023.
Biocon Biologics Limited Agreements
In July 2019, the Company entered into a manufacturing agreement, or the BBL manufacturing agreement, with a wholly-owned subsidiary of Biocon, Biocon Biologics Limited, or BBL, formerly Biocon Biologics India Limited, an affiliate of one of our greater than 5% stockholders. The BBL manufacturing agreement is valid for five years unless earlier terminated by one of the parties. Additionally, the Company entered into a material transfer agreement in August 2023, a quality agreement and a service agreement in October 2023 and a manufacturing agreement in December 2023, or, together with the BBL manufacturing agreement, the BBL Agreements, with BBL. Pursuant to the terms of the BBL Agreements, BBL manufactures and supplies specified quantities of products to the Company to be utilized in research and development and manufacturing pursuant to purchase orders executed from time to time between the parties. For the years ended December 31, 2023 and 2024, the Company incurred $1.2 million and $1.0 in research and development expenses, respectively, under the BBL Agreements. As of December 31, 2023 and 2024, the Company owed $0.0 million, respectively. The Company believes that all transactions with BBL have been entered into in the ordinary course of business.
45
Indemnification Agreements
We have entered into agreements to indemnify our directors and executive officers. These agreements, among other things, require us to indemnify these individuals for certain expenses (including attorneys’ fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or in our right, on account of any services undertaken by such person on behalf of our Company or that person’s status as a member of our board of directors to the maximum extent allowed under Delaware law.
Related Person Transaction Policy
Our board of directors reviews and approves transactions with directors, officers and holders of five percent or more of our voting securities and their affiliates, each a related party. The material facts as to the related party’s relationship or interest in the transaction are disclosed to our board of directors prior to their consideration of such transaction, and the transaction is not considered approved by our board of directors unless a majority of the directors who are not interested in the transaction approve the transaction. Further, when stockholders are entitled to vote on a transaction with a related party, the material facts of the related party’s relationship or interest in the transaction are disclosed to the stockholders, who must approve the transaction in good faith.
We have adopted a written related party transactions policy that such transactions must be approved by our audit committee.
46
PRINCIPAL STOCKHOLDERS
The following table sets forth information, to the extent known by us or ascertainable from public filings, with respect to the beneficial ownership of our common stock as of April 14, 2025 by:
•each of our directors;
•each of our named executive officers;
•all of our directors and executive officers as a group; and
•each person, or group of affiliated persons, who is known by us to beneficially owner of greater than 5.0% of our common stock.
The column entitled “Shares Beneficially Owned” is based on a total of 54,536,218 shares of our common stock outstanding as of April 14, 2025.
Beneficial ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with respect to our common stock. Shares of our common stock subject to options that are currently exercisable or exercisable within 60 days of April 14, 2025 are considered outstanding and beneficially owned by the person holding the options for the purpose of calculating the percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other person. Except as otherwise noted, the persons and entities in this table have sole voting and investing power with respect to all of the shares of our common stock beneficially owned by them, subject to community property laws, where applicable. Except as otherwise indicated in the table below, addresses of named beneficial owners are in care of Bicara Therapeutics Inc., 116 Huntington Avenue, Suite 703, Boston, MA 02116.
| Name of Beneficial Owner | Shares Beneficially Owned | Percentage of Shares Beneficially Owned | ||||||||||||
| Greater-than-five Percent Stockholders: | ||||||||||||||
Entities affiliated with Biocon(1) | 5,523,897 | 10.1 | % | |||||||||||
Entities affiliated with RA Capital Management, L.P. (2) | 6,955,993 | 12.8 | % | |||||||||||
Entities affiliated with Red Tree Venture Fund, L.P. (3) | 3,170,509 | 5.8 | % | |||||||||||
Invus Public Equities, L.P.(4) | 3,041,286 | 5.6 | % | |||||||||||
TPG GP A, LLC (5) | 3,010,425 | 5.5 | % | |||||||||||
FMR LLC(6) | 2,803,807 | 5.1 | % | |||||||||||
| Named Executive Officers and Directors: | ||||||||||||||
Claire Mazumdar, Ph.D., M.B.A (7) | 999,045 | 1.8 | % | |||||||||||
Ryan Cohlhepp, Pharm.D.(8) | 580,757 | 1.1 | % | |||||||||||
Ivan Hyep, M.B.A.(9) | 422,803 | * | ||||||||||||
Nils Lonberg, Ph.D.(10) | 63,933 | ** | ||||||||||||
| Carolyn Ng, Ph.D. | — | * | ||||||||||||
Kiran Mazumdar-Shaw (11) | 6,328,894 | 11.6 | % | |||||||||||
Jake Simson, Ph.D. (12 | 23,746 | ** | ||||||||||||
Kate Haviland, M.B.A.(13) | 46,059 | ** | ||||||||||||
Scott Robertson, M.B.A. (14) | 46,060 | ** | ||||||||||||
Michael Powell(15) | 11,157 | ** | ||||||||||||
Christopher Bowden(16) | 11,157 | ** | ||||||||||||
All executive officers and directors as a group (13 persons)(17) | 8,735,981 | 15.5 | % | |||||||||||
47
| * | Represents beneficial ownership of less than one percent. | ||||
| (1) | Information herein is based on a Form 4 filed with the SEC on September 16, 2024 by Biocon Ltd. Consists of (i) 4,443,122 shares of common stock held by Biocon Ltd, and (ii) 1,080,775 shares of common stock held by Biocon Pharma Inc. Kiran Mazumdar-Shaw, a member of our board of directors, is the managing member of Biocon Ltd and Biocon Pharma Inc. and may be deemed to have voting and dispositive power with respect to the shares held by Biocon Ltd and Biocon Pharma, and Ms. Mazumdar-Shaw may be deemed to beneficially own the shares held by Biocon Ltd. and Biocon Pharma. The address for Biocon Ltd is 20th KM, Hosur Road, Electronic City, Bangalore - 560100, and the address for Biocon Pharma is 485 State Hwy 1 South, Suite B 305, Iselin, NJ 08830. | ||||
| (2) | Information herein is based on a Schedule 13D filed with the SEC on September 16, 2024 by RA Capital Management, L.P. (“RA Capital”), Peter Kolchinsky, Rajeev Shah and RA Capital Healthcare Fund, L.P. (the “Fund”). RA Capital, Dr. Kolchinsky, Mr. Shah and the Fund are collectively referred to herein as the “RA Reporting Persons.” The RA Reporting Persons’ beneficial ownership of the Issuer’s Common Stock consists of (i) 4,303,418 shares of Common Stock directly held by the Fund; and (ii) 2,652,575 shares of Common Stock directly held by RA Capital Nexus Fund III, L.P. (the “Nexus Fund III”). RA Capital Healthcare Fund GP, LLC is the general partner of the Fund and RA Capital Nexus Fund III GP, LLC is the general partner of the Nexus Fund III. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for each of the Fund and the Nexus Fund III and may be deemed a beneficial owner of any securities of the Issuer held by the Fund or the Nexus Fund III. Each of the Fund and the Nexus Fund III has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in its portfolio, including the shares of the Issuer’s Common Stock reported herein. Because each of the Fund and the Nexus Fund III has divested itself of voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days’ notice, each of the Fund and the Nexus Fund III disclaims beneficial ownership of the securities it holds. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities. The business address of each RA Reporting Person is 200 Berkeley Street, 18th Floor, Boston, MA 02116. | ||||
| (3) | Information herein is based on a Schedule 13G filed with the SEC on September 16, 2024 by Red Tree Venture Fund, L.P. (“Red Tree LP”), Red Tree GP, LLC (“Red Tree GP”) and Heath Lukatch (“Lukatch” and, with Red Tree LP and Red Tree GP, collectively, the “Red Tree Reporting Persons”). Consists of 3,170,509 shares of Common Stock held by Red Tree LP. Red Tree GP serves as the sole general partner of Red Tree LP and shares voting and dispositive power over the shares owned by Red Tree LP. Lukatch is the Managing Director of Red Tree GP and shares voting and dispositive power over the shares held by Red Tree LP. The business address of each Red Tree Reporting Person is 2055 Woodside Road, Suite 270, Redwood City, CA 94061. | ||||
| (4) | Information herein is based on a Schedule 13G filed with the SEC on September 16, 2024 by Invus Public Equities, L.P. (“Invus Public Equities”), Invus Public Equities Advisors, LLC (“Invus PE Advisors”), Invus Global Management, LLC (“Global Management”), Siren, L.L.C. (“Siren”), Avicenna Life Sci Master Fund LP (“Avicenna Fund”), Avicenna Life Sci Master GP LLC (“Avicenna GP”), Ulys, L.L.C. (“Ulys”), and Raymond Debban (collectively, the “Invus Reporting Persons”). Invus Public Equities directly holds 3,041,286 Shares and Avicenna Fund directly holds 31,541 Shares. Invus PE Advisors, as the general partner of Invus Public Equities, controls Invus Public Equities and, accordingly, may be deemed to beneficially own the Shares directly held by Invus Public Equities. Global Management, as the managing member of Invus PE Advisors, controls Invus PE Advisors and, accordingly, may be deemed to beneficially own the Shares that Invus PE Advisors may be deemed to beneficially own. Siren, as the managing member of Global Management, controls Global Management and, accordingly, may be deemed to beneficially own the Shares that Global Management may be deemed to beneficially own. Avicenna GP, as the general partner of Avicenna Fund, controls Avicenna Fund and, accordingly, may be deemed to beneficially own the Shares directly held by Avicenna Fund. Ulys, as the managing member of Avicenna GP, controls Avicenna GP and, accordingly, may be deemed to beneficially own the Shares that Avicenna GP may be deemed to beneficially own. Mr. Raymond Debbane, as the managing member of Siren and Ulys, controls Siren and Ulys and, accordingly, may be deemed to beneficially own the Shares that Siren and Ulys may be deemed to beneficially own. The business address of each Invus Reporting Person is 750 Lexington Avenue, 30th Floor, New York, NY 10022. | ||||
48
| (5) | Information herein is based on a Schedule 13D filed jointly with the SEC on September 18, 2024 by TPG GP A, LLC, a Delaware limited liability company (“TPG GP A”), David Bonderman, James G. Coulter and Jon Winkelried (each a “TPG Reporting Person” and collectively, the “TPG Reporting Persons”). TPG GP A is the managing member of each of (i) TPG Group Holdings (SBS) Advisors, LLC, a Delaware limited liability company, which is the general partner of TPG Group Holdings (SBS), L.P., a Delaware limited partnership, and (ii) Alabama Investments (Parallel) GP, LLC, a Delaware limited liability company, which is the general partner of each of (a) Alabama Investments (Parallel), LP, a Delaware limited partnership, (b) Alabama Investments (Parallel) Founder A, LP, a Delaware limited partnership, and (c) Alabama Investments (Parallel) Founder G, LP, a Delaware limited partnership, which, collectively with TPG Group Holdings (SBS), L.P., Alabama Investments (Parallel), LP and Alabama Investments (Parallel) Founder A, LP, holds 100% of the shares of Class B common stock (which represents a majority of the combined voting power of the common stock) of TPG Inc., a Delaware corporation (“TPG”), which is the managing member of TPG GPCo, LLC, a Delaware limited liability company, which is the sole member TPG Holdings II-A, LLC, a Delaware limited liability company, which is the general partner of TPG Operating Group II, L.P., a Delaware limited partnership, which is the sole member of TPG Holdings I-A, LLC, a Delaware limited liability company, which is the general partner of TPG Operating Group I, L.P, a Delaware limited partnership, which is the sole member of TPG LSI GenPar Advisors, LLC, a Delaware limited liability company, which is the general partner of TPG LSI GenPar, L.P., a Delaware limited partnership, which is the sole member of TPG LSI SPV GP, LLC, a Delaware limited liability company, which is the general partner of each of (i) TPG LSI Rise Butterfly, L.P., a Delaware limited partnership (“TPG Butterfly I”), which directly holds 1,960,425 shares of Common Stock, and (ii) TPG LSI Rise Butterfly II, L.P., a Delaware limited partnership (“TPG Butterfly II” and, together with TPG Butterfly I, the “TPG Funds”), which directly holds 1,050,000 shares of Common Stock. Because of the relationship of TPG GP A to the TPG Funds, TPG GP A may be deemed to beneficially own the shares of Common Stock held by the TPG Funds. TPG GP A is controlled by entities owned by Messrs. Bonderman, Coulter and Winkelried. Because of the relationship of Messrs. Bonderman, Coulter and Winkelried to TPG GP A, each of Messrs. Bonderman, Coulter and Winkelried may be deemed to beneficially own the shares of Common Stock held by the TPG Funds. Messrs. Bonderman, Coulter and Winkelried disclaim beneficial ownership of the shares of Common Stock held by the TPG Funds except to the extent of their pecuniary interest therein. The business address of each TPG Reporting Person is c/o TPG Inc., 301 Commerce Street, Suite 3300, Fort Worth, Texas 76102. | ||||
| (6) | Information herein is based on a Schedule 13G filed with the SEC on March 3, 2025 by FMR LLC. and Abigail P. Johnson. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders’ voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders’ voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. FMR LLC has sole voting power over 2,803,063 shares of Common Stock and sole dispositive power over 2,803,807 of these shares of Common Stock, and Abigail P. Johnson has sole dispositive power over 2,803,807 of these shares of Common Stock. The business address of FMR LLC is 245 Summer Street, Boston, Massachusetts 02210 . | ||||
| (7) | Consists of (i) 309,892 shares of common stock and (ii) 689,153 shares of common stock subject to underlying options exercisable within 60 days of April 14, 2025. | ||||
| (8) | Consists of (i) 221,141 shares of common stock and (ii) 359,616 shares of common stock subject to underlying options exercisable within 60 days of April 14, 2025. | ||||
| (9) | Consists of (i) 145,355 shares of common stock and (ii) 277,448 shares of common stock subject to underlying options exercisable within 60 days of April 14, 2025. | ||||
| (10) | Consists of (i) 29,988 shares of common stock and (ii) 33,945 shares of common stock subject to underlying options exercisable within 60 days of April 14, 2025. | ||||
| (11) | See footnote 1 above. In addition, consists of (i) 324,552 shares of common stock held by Glentech International, a private company limited by shares of which Ms. Mazumdar-Shaw is the managing member, (ii) 432,736 shares of common stock held by Carica Investments, a partnership firm of which Ms. Mazumdar-Shaw is the managing partner, (iii) 16,669 shares of common stock held by Ms. Mazumdar Shaw and (iv) 31,040 shares of common stock subject to underlying options exercisable within 60 days of April 14, 2025. | ||||
| (12) | Consists of 23,746 shares of common stock subject to underlying options exercisable within 60 days of April 14, 2025. Dr. Simson holds these options for the benefit of the Fund and Nexus Fund III. Dr. Simson is obligated to turn over to RA Capital any net cash or stock received upon exercise of these options and, therefore, Mr. Simson disclaims beneficial ownership of these options and underlying common stock. | ||||
49
| (13) | Consists of (i) 7,437 shares of common stock and (ii) 38,622 shares of common stock subject to underlying options exercisable within 60 days of April 14, 2025. | ||||
| (14) | Consists of 46,060 shares of common stock subject to underlying options exercisable within 60 days of April 14, 2025. | ||||
| (15) | Consists of 11,157 shares of common stock subject to underlying options exercisable within 60 days of April 14, 2025. | ||||
| (16) | Consists of 11,157 shares of common stock subject to underlying options exercisable within 60 days of April 14, 2025. | ||||
| (17) | See notes (7) through (16) above; also includes (i) 35,497 shares of common stock and (ii) 157,122 shares of common stock subject to underlying options exercisable within 60 days of April 14, 2025 held by David Raben, M.D., the Company’s Chief Medical Officer and (iii) 9,751 shares of common stock subject to underlying options exercisable within 60 days of April 14, 2025 held by Lara Meisner, the Company’s Chief Legal Officer. | ||||
50
REPORT OF THE AUDIT COMMITTEE
The audit committee is appointed by the board of directors to assist the board of directors in fulfilling its oversight responsibilities with respect to (1) the integrity of Bicara Therapeutics’ financial statements and financial reporting process and systems of internal controls regarding finance, accounting, and compliance with legal and regulatory requirements, (2) the qualifications, independence, and performance of Bicara Therapeutics’ independent registered public accounting firm, (3) the performance of Bicara Therapeutics’ internal audit function, if any, and (4) other matters as set forth in the charter of the audit committee approved by the board of directors.
Management is responsible for the preparation of Bicara Therapeutics’ financial statements and the financial reporting process, including its system of internal control over financial reporting and its disclosure controls and procedures. The independent registered public accounting firm is responsible for performing an audit of Bicara Therapeutics’ financial statements in accordance with the standards of the Public Company Accounting Oversight Board (PCAOB) and issuing a report thereon. The audit committee’s responsibility is to monitor and oversee these processes.
In connection with these responsibilities, the audit committee reviewed and discussed with management and the independent registered public accounting firm the audited consolidated financial statements of Bicara Therapeutics for the fiscal year ended December 31, 2024. The audit committee also discussed with the independent registered public accounting firm the matters required to be discussed by the PCAOB’s Auditing Standard No. 1301, Communication with Audit Committees. In addition, the audit committee received written communications from the independent registered public accounting firm confirming their independence as required by the applicable requirements of the PCAOB and has discussed with the independent registered public accounting firm their independence.
Based on the reviews and discussions referred to above, the audit committee recommended to the board of directors that the audited consolidated financial statements of Bicara Therapeutics be included in Bicara Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2024, that was filed with the SEC. The information contained in this report shall not be deemed to be (1) “soliciting material,” (2) “filed” with the SEC, (3) subject to Regulations 14A or 14C of the Exchange Act, or (4) subject to the liabilities of Section 18 of the Exchange Act. This report shall not be deemed incorporated by reference into any of our other filings under the Exchange Act or the Securities Act, except to the extent that we specifically incorporate it by reference into such filing.
THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF BICARA THERAPEUTICS INC. | ||
Scott Robertson, M.B.A., Chairperson | ||
Carolyn Ng, Ph.D. | ||
| Michael Powell, Ph.D. | ||
April 25, 2025
51
HOUSEHOLDING
Some banks, brokers and other nominee record holders may be participating in the practice of “householding” proxy statements and annual reports. This means that only one copy of our documents, including the annual report to stockholders and proxy statement, may have been sent to multiple stockholders in your household. We will promptly deliver a separate copy of either document to you upon written or oral request to Bicara Therapeutics Inc., 116 Huntington Avenue, Suite 703, Boston, MA 02116, Attention: Corporate Secretary, telephone: 617-468-4219. If you want to receive separate copies of the proxy statement or annual report to stockholders in the future, or if you are receiving multiple copies and would like to receive only one copy per household, you should contact your bank, broker or other nominee record holder, or you may contact us at the above address and phone number.
STOCKHOLDER PROPOSALS
A stockholder who would like to have a proposal considered for inclusion in our 2026 proxy statement must submit the proposal in accordance with the procedures outlined in Rule 14a-8 of the Exchange Act so that it is received by us no later than December 16, 2025, which is 120 days prior to April 25, 2026. However, if the date of the 2026 annual meeting of stockholders is changed by more than 30 days from the date of the previous year’s meeting, then the deadline is a reasonable time before we begin to print and send our proxy statement for the 2026 annual meeting of stockholders. SEC rules set standards for eligibility and specify the types of stockholder proposals that may be excluded from a proxy statement. Stockholder proposals should be addressed to Bicara Therapeutics Inc., 116 Huntington Avenue, Suite 703, Boston, MA 02116, Attention: Corporate Secretary. We also encourage you to submit any such proposals via email to [email protected].
If a stockholder wishes to propose a nomination of persons for election to our board of directors or present a proposal at an annual meeting but does not wish to have the proposal considered for inclusion in our proxy statement and proxy card, our bylaws establish an advance notice procedure for such nominations and proposals. Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board of directors or by a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has delivered timely notice in proper form to our corporate secretary of the stockholder’s intention to bring such business before the meeting.
The required notice must be in writing and received by our corporate secretary at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary of the preceding year’s annual meeting. However, in the event that the date of the annual meeting is advanced by more than 30 days, or delayed by more than 60 days, from the first anniversary of the preceding year’s annual meeting, a stockholder’s notice must be so received no earlier than the 120th day prior to such annual meeting and not later than the close of business on the later of (A) the 90th day prior to such annual meeting and (B) the tenth day following the day on which notice of the date of such annual meeting was mailed or public disclosure of the date of such annual meeting was made, whichever first occurs. For stockholder proposals to be brought before the 2026 annual meeting of stockholders, the required notice must be received by our corporate secretary at our principal executive offices no earlier than February 9, 2026 and no later than March 11, 2026. Stockholder proposals and the required notice should be addressed to Bicara Therapeutics Inc., 116 Huntington Avenue, Suite 703, Boston, MA 02116, Attention: Corporate Secretary.
To comply with the SEC’s universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees must provide notice by the same deadline noted herein to submit a notice of nomination for the 2025 annual meeting of stockholders. Such notice must comply with the additional requirements of Rule 14a-19(b).
52
OTHER MATTERS
Our board of directors does not know of any other matters to be brought before the Annual Meeting. If any other matters not mentioned in this proxy statement are properly brought before the meeting, the individuals named in the enclosed proxy intend to use their discretionary voting authority under the proxy to vote the proxy in accordance with their best judgment on those matters.
53
54
55